



VALÉRIA AGUIAR GOMES

**“EFEITO DO ANTICONCEPCIONAL ORAL SOBRE AS
ALTERAÇÕES DE METALOPROTEINASES DA MATRIZ
EXTRACELULAR EM PACIENTES COM SÍNDROME DO
OVÁRIO POLICÍSTICO”**

***"EFFECT OF ORAL CONTRACEPTIVES ON CHANGES OF
EXTRACELLULAR MATRIX METALLOPROTEINASES IN
PATIENTS WITH POLYCYSTIC OVARY SYNDROME"***

Campinas

2012



UNIVERSIDADE ESTADUAL DE CAMPINAS
FACULDADE DE CIÊNCIAS MÉDICAS

VALÉRIA AGUIAR GOMES

**“EFEITO DO ANTICONCEPCIONAL ORAL SOBRE AS
ALTERAÇÕES DE METALOPROTEINASES DA MATRIZ
EXTRACELULAR EM PACIENTES COM SÍNDROME DO
OVÁRIO POLICÍSTICO”**

Orientador/ Supervisor: Prof. Dr. José Eduardo Tanus dos Santos

***"EFFECT OF ORAL CONTRACEPTIVES ON CHANGES OF
EXTRACELLULAR MATRIX METALLOPROTEINASES IN
PATIENTS WITH POLYCYSTIC OVARY SYNDROME"***

Tese de Doutorado apresentada ao Programa de
Pós-Graduação em Farmacologia da Faculdade de Ciências Médicas da
Universidade Estadual de Campinas para obtenção de título de Doutora em
Farmacologia.

Doctorate thesis presented to the Pharmacology
Postgraduation Programme of Medical Sciences of the University of Campinas to
obtain the Ph.D grade in Pharmacology

ESTE EXEMPLAR CORRESPONDE À VERSÃO
FINAL DA TESE DEFENDIDA POR VALÉRIA
AGUIAR GOMES, E ORIENTADA PELO PROF.
DR. JOSÉ EDUARDO TANUS DOS SANTOS.

Assinatura do Orientador

**CAMPINAS
2012**

FICHA CATALOGRÁFICA ELABORADA POR
ROSANA EVANGELISTA PODEROSO – CRB8/6652
BIBLIOTECA DA FACULDADE DE CIÊNCIAS MÉDICAS
UNICAMP

G585e Gomes, Valéria Aguiar, 1982 -
 Efeito do anticoncepcional oral sobre as alterações de
 metaloproteinases da matriz extracelular em pacientes
 com síndrome do ovário policístico / Valeria Aguiar
 Gomes. – Campinas, SP : [s.n.], 2012.

 Orientador: José Eduardo Tanus dos Santos.
 Tese (Doutorado) - Universidade Estadual de
 Campinas, Faculdade de Ciências Médicas.

 1. Metaloproteinases da matriz. 2. Ovário. 3.
 Andrógenos. 4. Anticoncepcionais orais. 5. Sistema
 cardiovascular – Doenças – Fatores de risco. I. Santos,
 José Eduardo Tanus dos. II. Universidade Estadual de
 Campinas. Faculdade de Ciências Médicas. III. Título.

Informações para Biblioteca Digital

Título em inglês: Effects of oral contraceptives on changes of extracellular matrix metalloproteinases in patients with polycystic ovary syndrome.

Palavras-chave em inglês:

Matrix metalloproteinase

Ovary

Androgens

Oral contraceptive

Cardiovascular system – Disease – Risk factors

Titulação: Doutora em Farmacologia

Banca examinadora:

José Eduardo Tanus dos Santos [Orientador]

Ilza Maria Urbano Monteiro

Luiz Guillermo Bahamondes

Paula Andrea de Albuquerque Salles Navarro

Valéria Cristina Sandrim

Data da defesa: 01-06-2012

Programa de Pós-Graduação: Farmacologia

Banca Examinadora de Tese de Doutorado

VALÉRIA AGUIAR GOMES

Orientador: Prof. Dr. José Eduardo Tanus dos Santos

Membros:

Prof. Dr. José Eduardo Tanus dos Santos

Profa. Dra. Ilza Maria Urbano Monteiro

Prof. Dr. Luis Guillermo Bahamondes

Profa. Dra. Paula Andrea Albuquerque Salles Navarro

Profa. Dra. Valeria Cristina Sandrim

Curso de pós-graduação em Farmacologia da Faculdade de Ciências Médicas da
Universidade Estadual de Campinas.

Data: 01/06/2012

DEDICATÓRIA

*Aos meus pais por serem meus exemplos, minha força,
meu alicerce e aos meus irmãos pelo amor e companheirismo.*

AGRADECIMENTOS

A DEUS por iluminar minha vida e ser minha fortaleza.

Aos meus pais por me ensinarem a sonhar e a não temer aos obstáculos que aparecem no caminho das realizações dos nossos sonhos. Ao meu pai por ser exemplo de persistência e dedicação, e a minha mãe por me ensinar diariamente que com amor e carinho somos capazes de conquistar as pessoas e o mundo. À minha irmã por ser minha companheira, confidente e parceira. Ao meu irmão pelo incentivo e apoio. À minha Tia Cléia por me amar desde sempre e por me ensinar que nunca é tarde para aprender e recomeçar. Aos meus avós, tias, tios, primos e primas que entenderam minha ausência e fizeram-se presentes com incentivo e carinho.

Às amigas-irmãs Danielly e Gizelle pois, além de serem exemplos, me mostraram que não existe distância que afaste uma amizade verdadeira. Às amigas, Vanessa, Joice e Flávia pelo companheirismo em todos os momentos. Às minhas florzinhas Lorena, Karina, Ana Carol, Daniele, Élen e Sandra. Vocês são muito especiais queridas. Ao meu amigo-irmão Alisson pelas longas conversas, pelos conselhos e principalmente pelo carinho.

Ao Professor Doutor José Eduardo Tanus dos Santos, não só pelas orientações, mas pela paciência e dedicação que, foram incentivos fundamentais para a realização deste trabalho. E por me ensinar que nos momentos de crise, crie.

À Dra. Carolina Sales Vieira pelas colaborações e sugestões indispensáveis, além do carinho e amizade.

AGRADECIMENTOS

Aos amigos do laboratório de Farmacologia, pelos momentos agradáveis vivenciados durante a realização deste trabalho e principalmente pela amizade.

Ao professor Doutor Edson Antunes, pela atenção e auxílio junto à coordenação da Pós-Graduação da Farmacologia.

Aos amigos do Laboratório de Farmacologia-UFMA, em especial a Prof. Dra Socorro Cartágenes e a Prof. Dra Marilene Oliveira da Rocha Borges, pela amizade, carinho e principalmente por terem despertado em mim o amor pela Farmacologia, a dedicação e o respeito pela profissão.

Às voluntárias que aceitaram participar desse estudo, sem as quais este projeto não existiria.

A Todos aqueles que contribuíram de alguma forma para a realização deste trabalho.

“Cria em mim Senhor, um coração puro, e um espírito reto”.

Salmo 50

RESUMO

A síndrome do ovário policístico (SOP) é a endocrinopatia mais comum em mulheres na idade reprodutiva e está frequentemente associada a alguns fatores de risco cardiovascular. A grande maioria das doenças cardiovasculares (DCV) ocorre inicialmente com o remodelamento vascular, em que as metaloproteinases de matriz (MMPs) são os principais mediadores. Sendo assim, o objetivo do presente estudo foi comparar os níveis plasmáticos da MMP-2 e da MMP-9 e dos inibidores teciduais de MMPs (TIMPs) das pacientes com SOP com as controles saudáveis e examinar se os níveis desses biomarcadores estão associados com às características clínicas e bioquímicas da SOP. Além disso, avaliar o efeito do anticoncepcional oral sobre os níveis plasmáticos de MMPs e respectivos inibidores endógenos nas mulheres com SOP. Para isso, na primeira parte do estudo, avaliamos 65 controles ovulatórias e 80 pacientes com SOP. As concentrações plasmáticas de MMP-8, MMP-9, TIMP-1, TIMP-2 foram medidas por Elisa e, as de MMP-2, por zimografia. Os níveis de MMP-2, MMP-8, MMP-9 e TIMP-1 não foram significativamente diferentes entre os grupos ($p \geq 0,05$). Pacientes com SOP apresentaram menores níveis plasmáticos de TIMP-2 do que as controles saudáveis ($182,30 \pm 5,60$ vs. $204,20 \pm 7,28$ ng/ml; $p \leq 0,05$). Além disso, a testosterona foi preditor independente dos níveis de TIMP-2 (estimativa = $-0,35$, $p = 0,04$) e da razão MMP-9/TIMP-1 (estimativa = $0,01$, $p = 0,04$). Para avaliar se a redução do hiperandrogenismo iria promover alguma alteração no perfil das MMPs, foram analisadas 20 mulheres com SOP que queriam contracepção hormonal (grupo SOP- ACO), 20 mulheres ovulatórias que desejavam contracepção hormonal (grupo controle- ACO) e 15 mulheres ovulatórias que desejavam contracepção não-hormonal (grupo controle). O

tratamento

com

ACO contendo 30 mcg de etinilestradiol/2mg de acetato de clormadinona durante 6 meses reduziu significativamente as concentrações plasmáticas de MMP-2 no grupo controle (de $1,44 \pm 0,11$ unidades arbitrárias no tempo basal para $1,22 \pm 0,07$ unidades arbitrárias após 6 meses; $p = 0,01$), e no grupo SOP (de $1,43 \pm 0,08$ unidades arbitrárias no tempo basal para $1,25 \pm 0,09$ unidades arbitrárias após 6 meses; $p = 0,007$). O ACO reduziu as concentrações de TIMP-2 e TIMP-1 no grupo controle (todos $p \leq 0,05$), mas não teve efeitos na MMP-9 plasmática e nas razões MMP-2/TIMP-2 e MMP-9/TIMP-1 (todos $p \geq 0,05$) nos grupos avaliados. Os achados do presente estudo indicam que as mulheres com SOP possuem um desequilíbrio nas razões MMP-2/TIMP-2 e MMP-9/TIMP-1, bem como níveis reduzidos de TIMP-2. Parte desses achados estão relacionados ao hiperandrogenismo presente nessas mulheres. Na segunda parte do estudo, observamos que a redução do hiperandrogenismo, promovido pelo tratamento em longo prazo com o ACO, reduziu as concentrações plasmáticas de MMP-2. Considerando o desequilíbrio no perfil das MMPs apresentado pelas mulheres com SOP e, as possíveis consequências decorrentes desse cenário, o tratamento com ACO se mostra benéfico nessas pacientes, podendo reduzir os riscos de futuras complicações cardiovasculares.

Palavras-chave: Metaloproteinase da matriz extracelular (MMP), Inibidor tecidual da matriz extracelular (TIMP), Síndrome do ovário policístico (SOP), Hiperandrogenismo, Anticoncepcional Oral (ACO), Risco cardiovascular.

ABSTRACT

The polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age and it is often associated with some cardiovascular risk factors. The majority of cardiovascular disease (CVD) occurs initially with vascular remodeling in which matrix metalloproteinases (MMPs) are key mediators. Therefore, the aim of this study was to compare plasma levels of MMP-2 and MMP-9 and tissue inhibitors of MMPs (TIMPs) of PCOS patients with healthy controls and to examine whether the levels of these biomarkers are associated with clinical and biochemical characteristics of PCOS. In addition to it, our goal was to evaluate the effect of oral contraceptives on plasma levels of MMPs and their endogenous inhibitors in women with PCOS. In order to prove it, in the first part of the study we evaluated 65 controls and 80 patients with ovulatory PCOS. The plasma concentration of MMP-8, MMP-9, TIMP-1 and TIMP-2 were measured by Elisa, and MMP-2 by zymography. The levels of MMP-2, MMP-8, MMP-9 and TIMP-1 were not significantly different between groups ($p \geq 0.05$). PCOS patients had lower their plasma levels of TIMP-2 than healthy controls ones ($182,30 \pm 5,60$ vs. $204,20 \pm 7,28$ ng/ml; $p = 0,02$). Furthermore, testosterone was an independent predictor of the levels of TIMP-2 (estimate = -0.35, $p = 0.04$) and the MMP-9/TIMP-1 ratio (estimate = 0.01, $p = 0.04$). To assess whether the reduction of hyperandrogenism would promote a change in the profile of MMPs, we analyzed 20 women with PCOS who wanted to hormonal contraception (OC-PCOS group), 20 ovulatory women who required hormonal contraception (OC-control group) and 15 ovulatory women who wanted non-hormonal contraception wanted a non-hormonal contraception (non-OC control group). Treatment with OC containing 2 mg chlormadinone acetate/30 μ g ethinylestradiol for 6 months significantly reduced

ABSTRACT

plasma

MMP-2

concentrations in the OC-control (from 1.44 ± 0.11 arbitrary units at baseline to 1.22 ± 0.07 arbitrary units after 6 months; $p = 0.01$) and the PCOS groups (from 1.43 ± 0.08 arbitrary units at baseline to 1.25 ± 0.09 arbitrary units after 6 months; $p = 0.007$) and TIMP-2 and TIMP-1 levels (448.0 ± 66.3 ng/mL versus 349.0 ± 40.9 ng/mL; $p = 0.009$) in the OC-control group (all $p \leq 0.05$) but had no effects on MMP-9 concentrations or on MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios (all $p \geq 0.05$) in any group. The results of this study indicate that women with PCOS have an imbalance in the MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios and reduced levels of TIMP-2. Parts of these findings are also related to hyperandrogenism presence in these women. In the second part of the study, we observed that the reduction of hyperandrogenism promoted by long-term treatment with the OC reduced plasma concentrations of MMP-2. Given the imbalance in the profile of MMPs presented by women with PCOS and the possible consequences of this scenario, treatment with OC shows beneficial in these patients may reduce the risk of future cardiovascular complications.

Keywords: Extracellular matrix metalloproteinase (MMP), Tissue inhibitor of extracellular matrix (TIMP), Polycystic ovary syndrome (PCOS), Hyperandrogenism, Oral Contraceptive (OC), Cardiovascular Risk.

LISTA DE SIGLAS E ABREVIATURAS

ACTH - adrenocorticotropina

ELISA - Enzyme-linked immunosorbent assay

DHEA - dehidroepiandrosterona

HDL - Lipoproteína de Alta Densidade

HOMA IR - Homeostasis model assessment insulin index- índice de resistência a insulina

IMC - Índice de massa corporal

LDL - Lipoproteína de Baixa Densidade

LH - Hormônio luteinizante

MEC - Membrana extracelular

mmHg - Milímetro de mercúrio

MMP - Metaloproteinases da Matriz extracelular

MT-MMP - Metaloproteinase da matriz extracelular do tipo membrana

PA - Pressão Arterial

SHBG - Hormônio sexual ligado a globulina

TIMP - Inibidor tecidual de metaloproteinase

SUMÁRIO

	PÁG.
RESUMO	viii
ABSTRACT	x
INTRODUÇÃO GERAL	14
Síndrome do Ovário Policístico.....	16
SOP e potenciais marcadores de doenças cardiovasculares.....	17
Metaloproteinases da matriz extracelular.....	19
Envolvimento das MMP-2 e MMP-9 em doenças cardiovasculares...	22
OBJETIVOS	26
CAPÍTULOS	28
Capítulo 1	29
Capítulo 2	36
DISCUSSÃO GERAL	42
CONCLUSÃO GERAL	55
REFERÊNCIAS BIBLIOGRÁFICAS	57
ANEXOS.....	65

INTRODUÇÃO GERAL

Síndrome do Ovário Policístico

A síndrome do ovário policístico (SOP) foi descrita pela primeira vez em 1935 por Stein e Leventhal, que observaram uma associação entre a amenorréia, o hirsutismo, ovários com aspecto policístico e obesidade. A SOP é uma das endocrinopatias mais frequentes em mulheres na idade reprodutiva, acometendo cerca de 6-10% delas em todo o mundo [1]. Atualmente, a SOP é caracterizada pela presença de duas dentre as seguintes características: hiperandrogenismo clínico e/ou bioquímico, anovulação crônica e/ou a presença de ovários policísticos no ultrassom [2]. O emprego de tais critérios permite o diagnóstico da SOP em mulheres com quatro fenótipos diferentes: 1) hiperandrogenismo, anovulação crônica e presença de ovários policísticos; 2) hiperandrogenismo, anovulação crônica e ovários normais; 3) hiperandrogenismo e ovários policísticos, porém com ciclos ovulatórios; e 4) anovulação crônica, ovários policísticos e leve aumento na concentração de androgênio plasmático.

Independente da heterogeneidade clínica observada entre as mulheres com SOP, as características mais frequentes nelas são a presença de ovários com padrão policístico, hirsutismo, acne, *acantose nigricans*, irregularidades menstruais e resistência à insulina.

Devido a sua diversidade e complexidade, a fisiopatologia da SOP ainda não está totalmente elucidada. No entanto, sugere-se que o ovário das mulheres com SOP sejam predispostos a hipersecretarem andrógenos, provavelmente desde a vida intra-uterina, e durante a ativação do eixo hipotálamo-hipófise-ovário que ocorre fisiologicamente no final da infância e início da puberdade.

INTRODUÇÃO

Os níveis elevados de testosterona circulante estimulam a pituitária a uma hiperprodução de hormônio luteinizante (LH) e também amplifica a resistência à insulina. O aumento das concentrações de LH e insulina ampliam ainda mais a produção de androgênio pelos ovários e, portanto, podem contribuir para o mecanismo de anovulação.

Alguns distúrbios metabólicos são comumente associados à SOP, entre eles: a resistência à insulina (prevalência de 50 a 70% nas pacientes com SOP [3]), diabetes mellitus do tipo 2 de início precoce, dislipidemia, hipertensão e obesidade, que além de serem componentes da síndrome metabólica são conhecidamente fatores de risco para as doenças cardiovasculares (DCV) [4-7].

Um estudo recente observou que a prevalência de síndrome metabólica em mulheres com SOP é cerca de oito vezes maior do que em mulheres não-SOP na mesma faixa etária [4]. Devido ao aumento da prevalência dessas comorbidades que, por sua vez, estão intimamente relacionadas ao risco cardiovascular nas mulheres com SOP, acredita-se que esse grupo de mulheres estaria mais predisposto ao desenvolvimento precoce de DCV.

SOP e potenciais marcadores de doenças cardiovasculares

Diversos estudos observaram a frequência pronunciada de fatores de risco para DCV em mulheres com SOP quando comparados com mulheres na mesma faixa etária. Entretanto, ainda é incerto o aumento da mortalidade por DCV nessas mulheres, já que até o presente momento não há estudos clínicos prospectivos com esta finalidade.

Contudo, diferentes estudos demonstraram alterações na função endotelial

INTRODUÇÃO

e aumento de alguns marcadores bioquímicos de DCV, assim como PAI-I, proteína C-reativa, adiponectina, endotelina-1 e marcadores de estresse oxidativo nas pacientes com SOP [4,8-11].

Achados como disfunção endotelial, que é um preditor para o desenvolvimento de DCV, aumento na espessura da camada íntima-média [12-14] e uma maior rigidez na artéria carótida [15] já foram relatados em mulheres com SOP. Os três fatores também são considerados marcadores precoces de mudanças estruturais na artéria que, posteriormente, podem resultar em eventos cardiovasculares como hipertrofia do ventrículo esquerdo e infarto do miocárdio. É importante ressaltar que a maior parte dos estudos inclui pacientes obesas e/ou hipertensas e/ou resistentes à insulina, fatores que poderiam, por si só, explicar parte desses resultados. Entretanto, um estudo recente mostrou aumento no índice da rigidez e redução na distensibilidade da artéria carótida em pacientes jovens e não obesas com SOP sem fatores de risco clássicos para doença cardiovascular [16].

A detecção precoce de mudanças estruturais em mulheres jovens com SOP é extremamente relevante, pois essas alterações estão associadas ao aumento da morbidade e mortalidade por DCV. Além disso, mulheres na pós-menopausa com características clínicas de SOP têm probabilidade de apresentar doença arterial coronariana 2,5 vezes maior do que as controles da mesma idade [17].

Em um estudo prospectivo foram avaliadas 61 mulheres com SOP e 85 mulheres controles durante nove anos. Observou-se que as mulheres com SOP apresentaram maior prevalência de calcificação na artéria coronária (45,9% vs

INTRODUÇÃO

30,6%) e na aorta (68,9% vs 55,3%) do que as controles. Esses resultados estão associados à presença de aterosclerose subclínica [18].

Sabe-se que o processo aterosclerótico é caracterizado por um remodelamento vascular da matriz extracelular e que as metaloproteinases de matriz (MMPs) têm sido implicadas como mediadores principais no estágio inicial de remodelamento vascular. Estudos também têm demonstrado o aumento da expressão de algumas MMPs na placa aterosclerótica, uma vez que a ativação das MMPs parece facilitar a instalação da aterosclerose, a desestabilização da placa e a agregação plaquetária [19-21]. Além de participar de processos patológicos como a formação de placa aterosclerótica, as MMPs também participam de processos fisiológicos como a ovulação [22] e o crescimento folicular [23].

Metaloproteinases da Matriz Extracelular

As metaloproteinases da matriz extracelular (MMPs) são uma família de mais de 20 subtipos de proteases zinco e cálcio-dependentes, estruturalmente relacionadas. Elas são caracterizadas pela habilidade de degradarem componentes da matriz extracelular, como o colágeno, fibronectina e várias proteoglicanas [24].

As MMPs participam das etapas de proliferação celular, diferenciação, remodelamento da matriz extracelular, vascularização e migração celular [25]. Elas exercem papéis importantes durante o remodelamento tecidual fisiológico como: o desenvolvimento embrionário, a morfogênese, a reprodução e reabsorção tecidual e, ainda, em processos patológicos que incluem reações

INTRODUÇÃO

inflamatórias, destruição da cartilagem na artrite, ruptura de placas ateroscleróticas, reestenose miocárdica, aneurismas, invasão neoplásica, entre outros.

As MMPs são classificadas de acordo com os substratos que degradam [26]. Desse modo, elas podem ser agrupadas em:

1. Colagenases (MMP-1, MMP-8, MMP-13 e MMP-18). Colagenases são responsáveis por clivar o colágeno fibrilar (colágenos do tipo I, II e III);
2. Gelatinases (MMP-2 e MMP-9). Degradam principalmente o colágeno desnaturado (gelatina);
3. Estromelinas (MMP-3 e MMP-10). Apesar de possuírem similaridade em relação ao substrato, a MMP-3 possui uma maior eficiência proteolítica quando comparada a MMP-10;
4. Matrilisinas (MMP-7 e MMP-26). Não possuem o domínio hemopexina;
5. MMPs do tipo membrana (MT1-MMP a MT8-MMP). A MT1-MMP pode degradar o colágeno do tipo I, II e II e outros componentes da matriz extracelular;
6. Metaloelastases (MMP-12).

Independentemente do substrato que degradam, as MMPs apresentam algumas similaridades estruturais. De um modo geral, elas constituem-se de um peptídeo sinal, um pró-domínio autoinibitório (domínio pró-peptídico), um domínio catalítico e um domínio hemopexina. O pró-domínio possui um domínio N-terminal, permitindo que a enzima seja transportada para o meio extracelular.

INTRODUÇÃO

O pró-domínio também contém uma cisteína que protege o domínio catalítico da enzima. A presença do íon zinco no domínio catalítico e o resíduo de cisteína são características comuns a todas MMPs. O domínio catalítico das gelatinases MMP-2 e MMP-9 é exclusivo, já que é o único que contém três fibronectinas do tipo 2, que formam um domínio de ligação com o colágeno, permitindo a junção e subsequente clivagem do mesmo. Com exceção das matrilisinas (MMP-7 e MMP-27), as MMPs contêm uma região flexível (de dobradura) que é conhecida como domínio hemopexina, o qual está ligado à cauda C-terminal.

As MMPs são secretadas na forma de precursores inativos (zimogênios) cuja latência é mantida através da interação entre o resíduo de cisteína, que está presente no pró-domínio, e o zinco presente no domínio catalítico, o que impede o acesso ao sítio ativo pelo substrato. Elas também podem ser ativadas por outras MMPs (ex: MT-MMPs) e por outras classes de proteases, como, por exemplo, a plasmina, que promove a clivagem do domínio pró-peptídico, deixando o sítio catalítico da enzima livre para interação com o respectivo substrato [24], ou por meio da ação não-proteolítica como o estresse oxidativo e detergentes [27].

A regulação da atividade proteolítica dessas enzimas pode ocorrer em vários níveis: 1) através da transcrição gênica; 2) tradução e síntese de zimogênios; 3) secreção dos zimogênios; 4) ativação dos zimogênios nos tecidos; 5) interação com inibidores teciduais de metaloproteinases (TIMPs) [24,28]. Esses inibidores teciduais são pequenas proteínas que agem formando um complexo na proporção de 1:1 com o zinco do domínio catalítico das MMPs promovendo, assim, um impedimento estérico dessas com os seus substratos.

INTRODUÇÃO

O equilíbrio tecidual entre MMPs e TIMPs é primordial para a dinâmica da degradação da matriz extracelular, sendo fundamental para a manutenção da homeostase tecidual [26]. Vários hormônios, assim como citocinas, angiotensina II, fatores de crescimento, estresse de cisalhamento e estresse oxidativo também podem interferir nessa regulação [29,26].

Envolvimento das MMP-2 e MMP-9 em doenças cardiovasculares

As ações proteolíticas das MMPs, entre outras funções, desempenham um importante papel no remodelamento vascular e na migração celular.

Dentre as diversas MMPs conhecidas, duas delas merecem destaque: a MMP-2 e a MMP-9. Essas duas MMPs degradam gelatina e colágeno do tipo IV e V e participam de alterações estruturais e funcionais observadas no remodelamento vascular presente em diversas doenças cardiovasculares [19,20].

Estudos com animais knock-out para a MMP-2 e MMP-9 têm observado que essas MMPs estão envolvidas na disfunção cardíaca, na ruptura após infarto do miocárdio e no desenvolvimento de aneurisma abdominal da aorta [30-32]. Além disso, diversos grupos têm demonstrado, tanto em estudos clínicos quanto experimentais um aumento significativo na atividade e expressão das MMP-2 e MMP-9 em várias doenças cardiovasculares, tais como aterosclerose, hipertensão e insuficiência cardíaca [33-35].

A MMP-2 é expressa constitutivamente e é amplamente distribuída pela maioria das células do tecido conjuntivo (fibroblastos), células endoteliais e epiteliais.

INTRODUÇÃO

Alguns trabalhos têm demonstrado o aumento da MMP-2 em amostras do miocárdio de pacientes com cardiomiopatia [35] e em modelos experimentais de hipertensão [36-38]. Estudos clínicos observaram, ainda, um aumento da MMP-2 plasmática em pacientes com insuficiência cardíaca [39-41] e na cardiomiopatia hipertrófica com disfunção sistólica [41]. Além disso, um aumento na expressão de MMP-2 foi evidenciado em aneurisma de aorta [42,19,43], e na restenose coronariana [42,19]. Além disso, a participação da MMP-2 também foi demonstrada durante a formação de lesões arteriais no processo aterosclerótico [44,45].

A MMP-9 também tem participação em algumas doenças cardiovasculares, podendo até ser considerada como um potencial marcador, sobretudo nas patologias com componente inflamatório, uma vez que ela é sintetizada e secretada por diversas células inflamatórias, como macrófagos e neutrófilos. Essa enzima também participa dos processos de migração e proliferação de células musculares lisas vasculares, pois permite que essas células rompam a barreira de tecido conjuntivo ao redor [42,46].

Os trabalhos que avaliaram as regiões vulneráveis de placas ateroscleróticas observaram que essa MMP estava altamente expressa. Dessa maneira, acredita-se que ela possua uma participação importante no remodelamento associado à aterosclerose e à ruptura dessas placas, o que pode resultar em eventos cardiovasculares fatais [21,20,19].

Níveis elevados da enzima também foram relatados em pacientes com angina instável [40], aneurisma de aorta [47], e naqueles que posteriormente apresentaram um evento cardiovascular fatal [48]. A elevação dos níveis foi

INTRODUÇÃO

relacionada à presença e severidade de DCV e à rigidez arterial em pacientes com doença arterial coronariana [39,40,49].

Estudos recentes têm revelado a participação da MMP-8, além da MMP-9 e da MMP-2, em placas instáveis na carótida [50,51]. O aumento dos níveis séricos e da expressão da MMP-8 também foi observado em lesões ateroscleróticas. O aumento da lesão foi proporcional com o aumento da expressão dessa enzima [52,53]. Trabalhos recentes encontraram uma associação entre a presença e severidade de doenças cardiovasculares com o aumento plasmático de MMP-8.

A fisiopatologia da SOP ainda não está totalmente esclarecida. Apesar disso, sabe-se que a SOP está intrinsecamente associada à resistência insulina, obesidade, hipertensão e dislipidemia que são fatores de risco para DC. Entretanto ainda não foram elucidados os mecanismos responsáveis pelo desenvolvimento de hipertensão e de outras comorbidades associadas com DC em mulheres com SOP. Sendo assim, o entendimento da fisiopatologia da SOP é essencial para a redução dos riscos cardiovasculares, aos quais as mulheres com SOP estão frequentemente expostas.

Como exposto, a MMP-2 e a MMP-9 são enzimas conhecidas por estarem envolvidas no desenvolvimento de hipertrofia ventricular esquerda [54,55], hipertensão [55,37,38], e no processo de ruptura de placa aterosclerótica [40,56]. Além disso, por estarem relacionadas a doenças cardiovasculares, torna-se pertinente avaliar as concentrações circulantes dessas enzimas, bem como investigar se o tratamento com o anticoncepcional oral pode alterar as concentrações dessas MMPs nas mulheres com SOP. Pois,

INTRODUÇÃO

o anticoncepcional oral é a droga de primeira escolha no tratamento das mulheres com SOP que desejam contracepção, uma vez q ele regula o ciclo menstrual, promove proteção endometrial e reduz o hiperandrogenismo nessas pacientes.

OBJETIVOS

OBJETIVOS

Os objetivos do primeiro artigo foram:

1. Determinar se existe alterações significativas nas concentrações plasmáticas de MMP-2 e MMP-9 e do TIMP-1 e TIMP-2 em pacientes com SOP quando comparadas com as do grupo controle.
2. Avaliar se os níveis desses biomarcadores estão associados com às características clínicas e bioquímicas da SOP.

O objetivo do segundo artigo foi:

1. Avaliar o efeito do anticoncepcional oral sobre os níveis plasmáticos de MMPs e respectivos inibidores endógenos nas mulheres com SOP.

CAPÍTULO

Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome

Valéria A. Gomes · Carolina S. Vieira · Anna L. Jacob-Ferreira ·
 Vanessa A. Belo · Gustavo M. Soares · Janaína B. F. Fernandes ·
 Rui A. Ferriani · Jose E. Tanus-Santos

Received: 15 December 2010 / Accepted: 17 March 2011 / Published online: 25 March 2011
 © Springer Science+Business Media, LLC. 2011

Abstract Altered levels of matrix metalloproteinases (MMPs) may reflect relevant pathogenetic mechanisms of disease conditions. The objective of this study was to compare the plasma levels of MMPs and tissue inhibitors of MMPs (TIMPs) in polycystic ovary syndrome (PCOS) patients with those found in healthy ovulatory controls and to examine whether the levels of these biomarkers are associated with clinical and biochemical features of this syndrome. Sixty-five healthy ovulatory subjects (controls) and 80 patients with PCOS were included in this study. MMP-2, MMP-8, MMP-9, TIMP-1, TIMP-2 concentrations were measured in plasma samples by gelatin zymography or enzyme-linked immunoassays. MMP-2, MMP-8, MMP-9, and TIMP-1 levels were similar in PCOS patients and in healthy controls ($P > 0.05$). PCOS patients had lower plasma TIMP-2 levels than healthy controls ($P < 0.05$). We found higher MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in PCOS patients than in healthy controls (all $P < 0.05$). Testosterone levels correlated positively with the MMP-9/

TIMP-1 ratio and negatively with TIMP-2 levels ($r = 0.26$, $P < 0.01$ and $r = -0.21$, $P = 0.02$, respectively). In addition, only testosterone was an independent predictor of TIMP-2 levels (estimate = -0.35 , $P = 0.04$) and the MMP-9/TIMP-1 ratio (estimate = 0.01 , $P = 0.04$). We found evidence indicating that the balance between MMPs and TIMPs in women with PCOS is altered, probably due to androgen excess found in these women.

Keywords Polycystic ovary syndrome · Hyperandrogenism · Metalloproteinases · Tissue inhibitors of metalloproteinases

Introduction

Polycystic ovary syndrome (PCOS) is the most common female endocrinopathy, affecting about 6–10% [1] of women of reproductive age. PCOS is characterized by hyperandrogenism, chronic anovulation, and/or polycystic ovaries on ultrasound [2]. The syndrome is also a multifaceted metabolic disease that is associated with insulin resistance, obesity, and metabolic syndrome [3–6], and this may contribute to increased risk of developing cardiovascular disease.

Although PCOS has been associated with a wide variety of cardiovascular risk factors, there is no definitive evidence for increased cardiovascular morbidity and mortality in women with PCOS. Nevertheless, endothelial dysfunction and elevated biochemical markers of cardiovascular and inflammatory disease have been demonstrated in women with PCOS [7–9]. In addition, studies found an increased intima-media thickness [10, 11] and increased stiffness in the carotid artery [12] in PCOS patients, both of which are early signs of arterial structural changes. However, the

V. A. Gomes · A. L. Jacob-Ferreira · V. A. Belo
 Department of Pharmacology, Faculty of Medical Sciences,
 State University of Campinas, Campinas, SP 13081-970, Brazil

C. S. Vieira · G. M. Soares · J. B. F. Fernandes · R. A. Ferriani
 Department of Gynecology and Obstetrics, Faculty of Medicine
 of Ribeirão Preto, University of São Paulo, Av. Bandeirantes,
 3900, Ribeirão Preto, SP 14049-900, Brazil

C. S. Vieira · R. A. Ferriani
 National Institute of Hormones and Women's Health,
 Ribeirão Preto, SP 14049-900, Brazil

J. E. Tanus-Santos (✉)
 Department of Pharmacology, Faculty of Medicine of Ribeirão
 Preto, University of São Paulo, Av. Bandeirantes, 3900,
 Ribeirão Preto, SP 14049-900, Brazil
 e-mail: tanus@fmrp.usp.br; tanussantos@yahoo.com

majority of studies included obese and/or hypertensive and/or insulin resistant patients, and these factors per se could explain part of these findings. In this respect, a recent study demonstrated an increased common carotid artery stiffness index and reduced distensibility of the carotid artery in young, non-obese PCOS patients without classical risk factors for cardiovascular disease [13]. These findings are associated with the presence of subclinical atherosclerosis.

It is known that the atherosclerotic process is characterized by vascular remodeling of the extracellular matrix. Matrix metalloproteinases (MMPs) have been implicated as primary mediators of this remodeling [14–16]. MMPs and tissue inhibitors of metalloproteinases (TIMPs) have been shown to play significant roles in many physiological conditions, including embryo implantation, angiogenesis, bone remodeling, ovarian follicular growth, and ovulation. They also contribute to pathological states, such as atherosclerosis, inflammation, and arthritis. MMP-2 and MMP-9 have been associated with cardiovascular disease [17], including atherosclerosis, coronary artery disease, and stroke [18–20], thus giving further support to the suggestion that MMP-2 and MMP-9 could play an important role in the development of cardiovascular diseases. Recently, it was suggested that circulating MMP-8 may be a marker of atherosclerosis [21–23]. The extent of remodeling of the extracellular matrix depends upon the critical equilibrium between MMPs and TIMPs. Studies have shown that alterations of circulating MMPs/TIMPs concentrations are implicated in the pathophysiology of a variety of cardiovascular diseases. The imbalance between MMPs and TIMPs has been observed in different contexts, including metabolic syndrome [24], obese children [25], and hypertensive disorders of pregnancy [26]. At present, only a limited number of studies have investigated possible alterations of circulating MMPs/TIMPs concentrations in women with PCOS [27–29]. In addition, there has been no evaluation of the circulating levels of MMP-8 in PCOS.

Due to the important association of the MMPs/TIMPs ratio with many cardiovascular diseases [23, 30], in the present study we assessed (1) whether there are significant alterations in the plasma concentrations of MMPs, TIMPs, and MMPs/TIMPs in PCOS young and non-obese patients compared with those found in healthy ovulatory controls and (2) the association between these markers and clinical and biochemical characteristics present in women with PCOS.

Materials and methods

Subjects and study protocol

A cross-sectional study was conducted at the University Hospital of the Faculty of Medicine of Ribeirão Preto,

University of São Paulo (HC-FMRP-USP), Brazil. The study protocol was approved by the local institutional review board, and all volunteers gave written informed consent. Eighty women with PCOS were included in the study immediately after diagnosis, and 65 healthy ovulatory women were recruited at a basic health unit before the prescription of a contraceptive method. Inclusion criteria were age between 18 and 35 years and BMI <30 kg/m². The diagnosis of PCOS was confirmed by the presence of at least two of the three criteria of the Rotterdam Consensus [31]: chronic anovulation, clinical, and/or biochemical signs of hyperandrogenism, and polycystic ovaries. Exclusion criteria for all subjects were smoking; alcoholism; drug addiction; current pregnancy; current or previous use (up to 2 months before the study) of oral, vaginal, monthly injectable, or transdermal hormonal contraceptives; current or previous use (up to 6 months before the study) of a long-lasting hormonal contraceptive method (injectable, implant, or intrauterine device); use of antiandrogenic or hypoglycemic drugs, anti-inflammatory drugs, or statins; presence of systemic diseases (diabetes mellitus type 2, cardiovascular diseases, autoimmune diseases, liver disease, thyroid disease, or congenital renal hyperplasia); personal history of arterial or venous thrombosis; chronic or acute inflammatory processes; and puerperium of 12 weeks or less. Inclusion criteria for ovulatory women were regular menstrual cycles, absence of clinical and laboratorial hyperandrogenism, and ultrasonography performed during the early follicular phase to confirm normal ovarian morphology.

Anthropometric measurements and laboratory tests

The following anthropometric variables were determined: weight, height, body mass index (BMI), and waist circumference (the lowest measurement found between the iliac crest and the inferior margin of the last rib). Blood samples were collected in the Gynecology Laboratory of HC-FMRP-USP between 8:00 and 9:00 a.m. after at least 10 h of fasting and always during the follicular phase (third to seventh day of the cycle) for control women and for women with PCOS and oligomenorrhea. PCOS patients with amenorrhea were evaluated after a pelvic ultrasonography showing no evidence of either a follicle equal to or greater than 10 mm or a corpus luteum. Samples of whole blood (20 ml) were collected and divided into tubes without anticoagulant (for serum separation) and in plastic conical tubes (BD-Becton-Dickinson, Plymouth, UK) with no vacuum and containing sodium citrate anticoagulant at 3.2% (in a fixed proportion of 9 parts whole blood to 1 part anticoagulant).

The blood samples were processed within a maximum of 2 h after collection. Serum was stored at −80°C for

simultaneous determination of the following serum variables: fasting serum glucose determined by the oxidase method using a Konelab 60i analyzer (Wiener Lab®, Rosario, Argentina); total cholesterol, HDL-cholesterol, and triglycerides (TG) determined by an enzymatic method using the BT 3000 plus analyzer (Wiener lab®); LDL-cholesterol as calculated according to the Friedewald formula [LDL-cholesterol = total cholesterol – (HDL-C + TG/5)] because none of the samples contained triglyceride levels exceeding 400 mg/dl [32]; ultrasensitive C reactive protein (CRP), sex hormone binding globulin (SHBG), and insulin were measured by chemoluminescence with the DPC Immulite® 2000 analyzer (Diagnostic Products Corporation, Los Angeles, CA, USA®); interleukin-6 (IL-6) was determined by chemoluminescence using the DPC Immulite® 1000 analyzer and the respective kits for Immulite® 1000 (Siemens®, CA, USA); and total testosterone was determined by radioimmunoassay using the Tri Carb 2100 TR scintillator (Packard® Instrument Company, Illinois, USA). The free androgen index (FAI) was calculated using the following formula: total testosterone (nmol/l)/SHBG (nmol/l) × 100 [33]. Insulin resistance was determined according to the homeostasis model assessment–insulin resistance (HOMA-IR) index, i.e., HOMA-IR = fasting serum glucose (mg/dl) × 0.05551 × fasting insulin (μU/ml)/22.5 [34].

Measurement of plasma MMP-9, MMP-8, TIMP-1, and TIMP-2 concentrations

Whole blood was centrifuged at 120×g (700 rpm) in a Sorvall RC 3 centrifuge (Sorvall Kendro Laboratory Products GmbH, Langenselbold, Germany) at room temperature (mean 22°C; range 18–24°C) for 15 min. Plasma was obtained by centrifuging the samples at 1600×g (2500 rpm) for 30 min using a Universal 32 R centrifuge (Hettich Zentrifugen, Tuttlingen, Germany) at 4°C. Plasma aliquots were stored at –70°C until they were analyzed. Concentrations of MMP-8, MMP-9, TIMP-1, and TIMP-2 were measured using a commercially available enzyme-linked immunosorbent (ELISA) assay kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.

SDS-polyacrylamide gel electrophoresis (PAGE) gelatin zymography of MMP-2

Gelatin zymography of MMP-2 from plasma samples was performed as previously described [35–37]. Briefly, plasma samples were subjected to electrophoresis on 7% SDS-PAGE co-polymerized with gelatin (1%) as the substrate. After electrophoresis was complete, the gel was incubated for 1 h at room temperature in a 2% Triton X-100 solution

and incubated at 37°C for 16 h in Tris–HCl buffer, pH 7.4, containing 10 mmol/l CaCl₂. The gels were stained with 0.05% Coomassie Brilliant Blue G-250 and then destained with 30% methanol and 10% acetic acid. Gelatinolytic activities were detected as unstained bands against the background of Coomassie blue-stained gelatin. Enzyme activity was assayed by densitometry using ImageJ version 1.42q (Wayne Rasband National Institutes of Health, USA). MMP-2 was identified as a band at 72 kDa by the relation of log Mr to the relative mobility of Sigma SDS-PAGE LMW marker proteins.

Statistical analysis

All the results were expressed as mean ± SEM. An unpaired Student's *t* test was used to compare normally distributed variables. The Mann–Whitney *U* test was used to compare non-normally distributed variables. Spearman's correlation was applied to calculate the correlation between the variables. Data were analyzed using SPSS 16.0 for Windows (SPSS Inc., Chicago, Illinois, USA).

Univariate analyses were performed to assess the relationship between MMPs or TIMPs concentrations and clinical variables that could influence their levels. HOMA, BMI, PCOS, and testosterone levels were included as independent variables in a multiple linear regression model to explain changes in MMPs, TIMPs, and the MMPs/TIMPs ratio using SAS 9.0 software (SAS Institute Inc., Cary, NC, USA). The results were defined as statistically significant when *P* < 0.05.

Results

The clinical characteristics of all participants are summarized in Table 1. We found no significant differences in age, diastolic arterial pressure (DAP), lipid profile, fasting serum glucose, IL-6, and CRP when controls were compared with patients with PCOS (all *P* > 0.05). However, patients with PCOS had higher BMIs and HOMA (all *P* < 0.05) than in controls. The mean systolic arterial pressure and waist circumference were higher in PCOS patients than in controls but was within normal limits (all *P* < 0.01). In addition, PCOS patients had a greater ovarian volume. Similarly, total testosterone and FAI were higher in PCOS patients than in controls, and SHBG levels were lower in women with PCOS than in controls (all *P* < 0.01).

Patients with PCOS had significant lower plasma TIMP-2 concentrations compared with those found in controls (182.30 ± 5.60 vs. 204.20 ± 7.28 ng/ml; *P* = 0.02; Table 2), while MMP-2, MMP-9, MMP-8, and TIMP-1 levels did not differ significantly between groups (all *P* > 0.05; Table 2). However, we found higher MMP-2/

Table 1 Clinical and laboratory characteristics of the study groups

	Controls (<i>n</i> = 65)	PCOS (<i>n</i> = 80)	<i>P</i> value
Age (years)	23.54 ± 0.56	24.40 ± 0.44	0.09 ^a
BMI (kg/m ²)	22.86 ± 0.39	26.43 ± 0.73	<0.01 ^a
WC (cm)	72.81 ± 0.91	86.06 ± 1.79	<0.01 ^a
SAP (mmHg)	112.10 ± 1.07	117.60 ± 1.24	<0.01 ^a
DAP (mmHg)	76.26 ± 0.89	78.69 ± 0.92	0.06 ^b
Ovarian volume (cm ³)	6.60 ± 0.21	11.70 ± 0.40	<0.01 ^a
TChol (mg/dl)	168.60 ± 2.57	173.10 ± 3.69	0.53 ^a
TG (mg/dl)	76.56 ± 5.49	92.99 ± 5.94	0.22 ^a
HDL (mg/dl)	50.80 ± 0.90	49.84 ± 1.03	0.37 ^a
LDL (mg/dl)	101.60 ± 2.14	104.70 ± 3.11	0.62 ^a
Glycemia (mg/dl)	88.67 ± 0.56	87.55 ± 1.05	0.34 ^a
Insulin (μU/ml)	5.50 ± 0.31	11.07 ± 1.44	0.01 ^a
HOMA-IR	1.22 ± 0.07	2.45 ± 0.34	0.03 ^a
Testosterone (ng/dl)	52.18 ± 1.66	77.67 ± 3.58	<0.01 ^a
SHBG (nmol/l)	46.93 ± 1.40	35.51 ± 2.12	<0.01 ^a
FAI (%)	4.44 ± 0.20	9.64 ± 0.89	<0.01 ^a
Interleukin-6 (pg/ml)	1.71 ± 0.10	2.02 ± 0.15	0.58 ^a
CRP (mg/l)	3.83 ± 0.62	2.46 ± 0.36	0.36 ^a

Values are the mean ± S.E.M

BMI body mass index, WC waist circumference, SAP systolic arterial pressure, DAP diastolic arterial pressure, TChol total cholesterol, TG Triglycerides, HOMA-IR homeostasis model assessment-insulin resistance, SHBG sex hormone binding globulin, FAI free androgen index, CRP C reactive protein

^a *P* value obtained by the Mann–Whitney test

^b *P* value obtained by the unpaired *t* test

Table 2 MMP and TIMP profile in PCOS patients and controls

	Controls (<i>n</i> = 65)	PCOS (<i>n</i> = 80)	<i>P</i> value
MMP-2 (arbitrary units)	0.99 ± 0.03	1.01 ± 0.03	0.66
MMP-9 (ng/ml)	146.80 ± 10.52	175.90 ± 12.45	0.07
MMP-8 (ng/ml)	496.10 ± 49.54	598.50 ± 68.13	0.78
TIMP-2 (ng/ml)	204.20 ± 7.28	182.30 ± 5.60	0.02
TIMP-1 (ng/ml)	479.10 ± 29.11	427.30 ± 21.54	0.30
MMP-2/TIMP-2 ratio (×1000)	5.19 ± 0.25	5.91 ± 0.25	0.02
MMP-9/TIMP-1 ratio	0.36 ± 0.03	0.48 ± 0.04	0.01

Values are the mean ± S.E.M

P value obtained by the Mann–Whitney test

TIMP-2 and MMP-9/TIMP-1 ratios in women with PCOS than in controls (all *P* < 0.05; Table 2).

We examined the correlation between MMPs and TIMPs with clinical characteristics of all participants in both groups. MMP-9 was positively correlated with MMP-8 (*r* = 0.20, *P* = 0.01), and MMP-8 levels were positively correlated with TIMP-1 (*r* = 0.43, *P* < 0.01) and negatively with triglycerides levels (*r* = −0.24, *P* < 0.01). Waist circumference (*r* = 0.20, *P* = 0.02), glucose (*r* = 0.21, *P* = 0.02), and testosterone (*r* = 0.26, *P* < 0.01) were positively correlated with the MMP-9/TIMP-1 ratio.

To determine the influence of PCOS and certain variables (HOMA, BMI, and testosterone) on MMPs, TIMPs, and MMPs/TIMPs ratios, we performed a multiple linear regression analysis (Table 3). HOMA-IR was significantly related to the MMP-9/TIMP-1 ratio when not considering BMI in the multiple regression model (data not shown). However, testosterone was an independent predictor of TIMP-2 levels (estimate = −0.35, *P* = 0.04) and of the MMP-9/TIMP-1 ratio (estimate = 0.01, *P* = 0.04).

Discussion

The main findings of the present study in women with PCOS are that: (i) compared with healthy subjects, patients with PCOS have an imbalance between MMPs and TIMPs, including lower concentrations of TIMP-2 and increased MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios and (ii) TIMP-

Table 3 Results from multiple linear regression analyses for MMP, TIMPs, and MMPs/TIMPs ratios using PCOS as an independent variable

	MMP-2 (<i>R</i> ² = 0.05)		MMP-9 (<i>R</i> ² = 0.03)		MMP-8 (<i>R</i> ² = 0.03)		TIMP-2 (<i>R</i> ² = 0.07)		TIMP-1 (<i>R</i> ² = 0.06)		MMP-2/TIMP-2 (<i>R</i> ² = 0.03)		MMP-9/TIMP-1 (<i>R</i> ² = 0.09)	
	<i>E</i>	<i>P</i>	<i>E</i>	<i>P</i>	<i>E</i>	<i>P</i>	<i>E</i>	<i>P</i>	<i>E</i>	<i>P</i>	<i>E</i>	<i>P</i>	<i>E</i>	<i>P</i>
PCOS	0.05	0.45	0.03	0.78	0.26	0.16	1.37	0.90	0.02	0.83	0.001	0.70	0.01	0.94
HOMA	0.01	0.66	0.02	0.28	−0.02	0.61	−2.41	0.27	−0.01	0.64	0.001	0.17	0.03	0.21
Testosterone	−0.01	0.11	0.01	0.45	0.01	0.67	−0.35	0.04	−0.01	0.06	0.001	0.54	0.01	0.04
BMI	−0.01	0.07	−0.01	0.99	−0.01	0.96	−0.31	0.74	−0.01	0.33	−0.001	0.17	0.01	0.45

E estimate

2 was negatively related to testosterone levels, while the MMP-9/TIMP-1 ratio was positively related to testosterone levels. To our knowledge, this is the first study showing evidence for a negative association between testosterone and TIMP-2 and a positive association between testosterone and the MMP-9/TIMP-1 ratio. Our results suggest that the hyperandrogenism present in most women with PCOS can be a contributor to cardiovascular risk because there is a link between the imbalance in MMPs/TIMPs ratios and cardiovascular disease.

The MMPs constitute a large family of proteolytic enzymes that degrade the extracellular matrix and facilitate remodeling under normal and pathological conditions [30]. MMPs can be strictly regulated at multiple levels through the control of gene transcription, posttranslational activation of zymogens, and the interactions of secreted MMPs with TIMPs, which are small proteins that inhibit MMPs by noncovalently binding them with a 1:1 stoichiometry. TIMP-1 and TIMP-2 are the major inhibitors of MMP-9 and MMP-2, respectively [30]. In the present study, we found reduced levels of TIMP-2 and an elevated MMP-2/TIMP-2 ratio in women with PCOS when compared with healthy controls. In addition to inhibiting MMPs, TIMP-2 may inhibit the migration and apoptosis of macrophages and foam cells. Moreover, studies have demonstrated that TIMP-2 is also involved in the activation of MMP-2. At low concentrations, TIMP-2 serves as a receptor for MMP-2, forming the membrane-type matrix metalloproteinase 1-TIMP-2 (MT1-MMP-TIMP-2) complex and consequently leading to MMP-2 activation [38, 39]. However, at high concentrations, TIMP-2 neutralizes membrane-type matrix metalloproteinase 1 (MT-MMP-1) and prevents MMP-2 activation [38, 39]. Therefore, changes in TIMP-2 can contribute to an imbalance in the MMP-2/TIMP-2 ratio, favoring extracellular degradation. In spite of higher MMP-9 levels and lower TIMP-1 levels in the group of PCOS women, these differences were not statistically significant when compared with control group. However, these alterations contributed to higher MMP-9/TIMP-1 ratio observed in the PCOS group.

Our findings showing that women with PCOS have higher MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios than ovulatory controls are in agreement with previous studies [27, 29]. These results are important because a critical equilibrium between MMPs and TIMPs determines extracellular matrix degradation, and alterations in the MMPs/TIMPs ratios may lead to disease conditions. Therefore, the assessment of MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios may be better markers of net MMPs activities.

The MMP-9 and MMP-2 levels in the present study were not significantly different between PCOS patients and healthy controls. These findings are in contrast with previous studies [27, 29] that reported higher serum

concentrations of MMP-9 [27, 29] and MMP-2 [29] in women with PCOS than in controls. It is possible that the small sample size and the use of serum samples instead of plasma, could explain the difference observed between the studies. Indeed, previous studies used serum samples to assess circulating levels of MMPs, and serum samples can artificially increase MMP-9 levels [35–37].

Most women with PCOS exhibit a clustering of cardiovascular risk factors, including obesity and insulin resistance. Indeed, BMI and HOMA-IR were significantly higher in PCOS women compared with control women enrolled in the present study, even though BMI <30 kg/m² was used as an inclusion criteria. We evaluated the potential impact of BMI and insulin resistance on MMPs and TIMPs levels. However, these markers of cardiovascular risk were not relevant predictors of MMPs or TIMPs levels. These findings are not enough to completely rule out the possibility that insulin resistance and obesity contribute to imbalanced MMPs/TIMPs under other conditions.

We found a negative correlation between plasma TIMP-2 concentrations and testosterone levels. We also found a positive correlation between the MMP-9/TIMP-1 ratio and testosterone. These results are consistent with reduced levels of TIMP-2 and an increased MMP-9/TIMP-1 ratio, which confirms the findings obtained when we compared PCOS patients with ovulatory women. Hyperandrogenism is a major component of PCOS, and the association between testosterone, TIMP-2, and MMP-9/TIMP-1 ratio suggests a role for testosterone in the augmentation of cardiovascular risk factors. In a multivariate model, testosterone was also an independent predictor of TIMP-2 levels and the MMP-9/TIMP-1 ratio. The Rotterdam criteria for PCOS include four phenotypes of polycystic ovary syndrome, and only one phenotype does not require clinical hyperandrogenism for the diagnosis [40]. Women with the three phenotypes that include hyperandrogenism have higher levels of cardiovascular risk markers [41, 42]. Previously, Luque-Ramírez [42] compared control women with PCOS patients, and the carotid intima-media thickness was increased in PCOS women independently of obesity and was directly related to hyperandrogenism, suggesting that androgen excess is associated with cardiovascular risk. Our data suggest that hyperandrogenism, and not the PCOS diagnosis, is the major factor in the imbalance in the MMPs/TIMPs ratios found in women with PCOS. However, future studies are necessary to confirm these findings and to determine the mechanisms explaining the interaction between MMPs/TIMPs ratios and testosterone.

In conclusion, we found evidence that the plasma MMPs/TIMPs profile is altered in PCOS. Patients with PCOS have lower TIMP-2 levels and higher MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios when compared with


controls. Furthermore, total testosterone is an independent predictor of TIMP-2 levels and MMP-9/TIMP-1 ratio. Together, these results suggest that hyperandrogenism is a key characteristic in women with PCOS that may contribute to an imbalance between MMPs and TIMPs, therefore this scenario can favor an increased risk of developing cardiovascular diseases in this group of women with PCOS. Pharmacological interventions focusing on MMPs may be justified in patients with PCOS.

Acknowledgments This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo and Conselho Nacional de Desenvolvimento Científico e Tecnológico.

References

- Carmina E, Lobo RA (1999) Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. *J Clin Endocrinol Metab* 84(6): 1897–1899
- Group. TREA-SPCW (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril* 81(1):19–25
- Apridonidze T, Essah PA, Iuorno MJ, Nestler JE (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 90(4): 1929–1935
- Legro RS, Kusanman AR, Dodson WC, Dunaif A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. *J Clin Endocrinol Metab* 84(1):165–169
- Norman RJ (2001) Obesity, polycystic ovary syndrome and anovulation—how are they interrelated? *Curr Opin Obstet Gynecol* 13(3):323–327
- Norman RJ, Masters S, Hague W (1996) Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. *Fertil Steril* 66(6):942–947
- Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Paterakis T, Lekakis J, Panidis D (2006) Inflammatory and endothelial markers in women with polycystic ovary syndrome. *Eur J Clin Invest* 36(10):691–697
- Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S, Mittermayer F, Wolzt M, Krzyzanowska K, Randevara H, Scherthaner G, Lehnert H (2008) Asymmetrical dimethyl-arginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. *J Clin Endocrinol Metab* 93(1):82–90
- Gonzalez F, Rote NS, Minium J, Kirwan JP (2009) Evidence of proatherogenic inflammation in polycystic ovary syndrome. *Metabolism* 58(7):954–962
- Vural B, Caliskan E, Turkoz E, Kilic T, Demirei A (2005) Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. *Hum Reprod* 20(9):2409–2413
- Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G, Colao A (2004) Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 89(9):4588–4593
- Lakhani K, Scifalian AM, Hardiman P (2002) Impaired carotid viscoelastic properties in women with polycystic ovaries. *Circulation* 106(1):81–85
- Soares GM, Vieira CS, Martins WP, Franceschini SA, dos Reis RM, Silva de Sa MF, Ferriani RA (2009) Increased arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS) without comorbidities: one more characteristic inherent to the syndrome? *Clin Endocrinol (Oxf)* 71(3):406–411
- Sapienza P, di Marzo L, Borrelli V, Sterpetti AV, Mingoli A, Cresti S, Cavallaro A (2005) Metalloproteinases and their inhibitors are markers of plaque instability. *Surgery* 137(3): 355–363
- Johnson JL, Jackson CL, Angelini GD, George SJ (1998) Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. *Arterioscler Thromb Vasc Biol* 18(11):1707–1715
- Formato M, Farina M, Spirito R, Maggioni M, Guarino A, Cherchi GM, Biglioli P, Edelstein C, Scanu AM (2004) Evidence for a proinflammatory and proteolytic environment in plaques from endarterectomy segments of human carotid arteries. *Arterioscler Thromb Vasc Biol* 24(1):129–135
- Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L (2003) Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. *Circulation* 107(12):1579–1585
- Creemers EE, Cleutjens JP, Smits JF, Daemen MJ, van den Borne SW, Hanemaaijer R, Blankesteijn WM (2001) Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. *Circ Res* 89(3):201–210
- Fatar M, Stroick M, Griebel M, Hennerici M, Creemers EE, Cleutjens JP, Smits JF, Daemen MJ, van den Borne SW, Hanemaaijer R, Blankesteijn WM (2005) Matrix metalloproteinases in cerebrovascular diseases Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. *Cerebrovasc Dis* 20(3):141–151
- van den Borne SW, Cleutjens JP, Hanemaaijer R, Creemers EE, Smits JF, Daemen MJ, Blankesteijn WM (2009) Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. *Cardiovasc Pathol* 18(1):37–43
- Molloy KJ, Thompson MM, Jones JL, Schwalbe EC, Bell PR, Naylor AR, Loftus IM (2004) Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. *Circulation* 110(3): 337–343
- Tuomainen AM, Nyyssönen K, Laukkanen JA, Tervahartiala T, Tuomainen TP, Salonen JT, Sorsa T, Pussinen PJ (2007) Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. *Arterioscler Thromb Vasc Biol* 27(12):2722–2728
- Laxton RC, Hu Y, Duchene J, Zhang F, Zhang Z, Leung KY, Xiao Q, Scotland RS, Hodgkinson CP, Smith K, Willeit J, Lopez-Otin C, Simpson IA, Kiechl S, Ahluwalia A, Xu Q, Ye S (2009) A role of matrix metalloproteinase-8 in atherosclerosis. *Circ Res* 105(9):921–929
- Goncalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, Marcaccini AM, Gerlach RF, Tanus-Santos JE (2009) Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. *Clin Chim Acta* 403(1–2):173–177
- Belo VA, Souza-Costa DC, Lana CM, Caputo FL, Marcaccini AM, Gerlach RF, Bastos MG, Tanus-Santos JE (2009) Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9,

- and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. *Clin Biochem* 42(10–11):984–990
26. Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE (2008) Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. *Clin Biochem* 41(10–11):875–880
 27. Liu B, Cai LY, Lv HM, Xia L, Zhang YJ, Zhang HX, Guan YM (2008) Raised serum levels of matrix metalloproteinase-9 in women with polycystic ovary syndrome and its association with insulin-like growth factor binding protein-1. *Gynecol Endocrinol* 24(5):285–288
 28. Diamanti-Kandarakis E, Livadas S, Kandarakis SA, Margeli A, Papassotiropoulos I (2008) Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism? *Eur J Endocrinol* 158(4):525–531
 29. Lewandowski KC, Komorowski J, O'Callaghan CJ, Tan BK, Chen J, Prelevic GM, Rande HS (2006) Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. *J Clin Endocrinol Metab* 91(3):1173–1177
 30. Raffetto JD, Khalil RA (2008) Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. *Biochem Pharmacol* 75(2):346–359
 31. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Hum Reprod* 19(1):41–47
 32. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 18(6):499–502
 33. Mathur RS, Moody LO, Landgrebe S, Williamson HO (1981) Plasma androgens and sex hormone-binding globulin in the evaluation of hirsute females. *Fertil Steril* 35(1):29–35
 34. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 28(7):412–419
 35. Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos JE (2005) Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. *Clin Biochem* 38(5):410–414
 36. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE (2005) Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. *Anal Biochem* 344(1):147–149
 37. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE (2007) Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. *Clin Biochem* 40(1–2):119–123
 38. Worley JR, Thompkins PB, Lee MH, Hutton M, Soloway P, Edwards DR, Murphy G, Knauper V (2003) Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). *Biochem J* 372(Pt 3):799–809
 39. Cowell S, Knauper V, Stewart ML, D'Ortho MP, Stanton H, Hembry RM, Lopez-Otin C, Reynolds JJ, Murphy G (1998) Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. *Biochem J* 331(Pt 2):453–458
 40. Norman RJ, Dewailly D, Legro RS, Hickey TE (2007) Polycystic ovary syndrome. *Lancet* 370(9588):685–697
 41. Camina E, Chu MC, Longo RA, Rini GB, Lobo RA, Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF (2005) Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. *J Clin Endocrinol Metab* 90(5):2545–2549
 42. Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF (2007) Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. *Hum Reprod* 22(12):3197–3203

	B	C	P	T		8	9	5	B	Dispatch: 2.5.12	Journal: BCPT	CE: Surya P.
	Journal Name				Manuscript No.					Author Received:	No. of pages: 6	PE: Devipriya

Oral Contraceptive Containing Chlormadinone Acetate and Ethinylestradiol Reduces Plasma Concentrations of Matrix Metalloproteinase-2 in Women with Polycystic Ovary Syndrome

Valéria A. Gomes¹, Carolina S. Vieira^{2,3}, Anna L. Jacob-Ferreira¹, Vanessa A. Belo¹, Gustavo M. Soares², Janaína B. França², Rui A. Ferriani^{2,3} and Jose E. Tanus-Santos⁴

¹Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas, Campinas, SP, Brazil, ²Department of Gynecology and Obstetrics, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil, ³National Institute of Hormones and Women's Health, Ribeirão Preto, SP, Brazil and ⁴Department of Pharmacology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil

(Received 23 March 2012; Accepted 10 April 2012)

Abstract: Biochemical markers of cardiovascular disease, including matrix metalloproteinases (MMPs), are altered in women with polycystic ovary syndrome (PCOS), with many of these alterations thought to be due to excess androgen concentrations. Despite oral contraceptives (OCs) being the first-line pharmacological treatment in women with PCOS and the importance of MMPs in many physiological conditions and pathological states, including cardiovascular diseases, no study has yet evaluated whether OCs alter plasma concentrations of MMPs. We therefore assessed whether treatment with an OC containing the anti-androgenic progestogen alters MMP profiles in women with PCOS. We analysed 20 women with PCOS who wanted hormonal contraception (OC-PCOS group), 20 ovulatory women who required hormonal contraception (OC-control group) and 20 ovulatory women who wanted non-hormonal contraception (non-OC-control group). OC consisted of cyclic use of 2 mg chlormadinone acetate/30 µg ethinylestradiol for 6 months. Plasma concentrations of MMP-2, MMP-9, TIMP-1 and TIMP-2 were measured by gelatin zymography or enzyme-linked immunoassays. OC treatment for 6 months significantly reduced plasma MMP-2 concentrations in the OC-control and OC-PCOS groups and TIMP-2 and TIMP-1 concentrations levels in the OC-control group (all $p < 0.05$), but had no effects on MMP-9 concentrations or on MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in any group (all $p > 0.05$). These findings indicated that long-term treatment with an OC containing chlormadinone acetate plus ethinylestradiol reduced plasma MMP-2 concentrations in both healthy and PCOS women. As the latter have imbalances in circulating matrix MMPs, treatment of these women with an OC may be beneficial.

Matrix metalloproteinases (MMPs) are a large endogenous family of proteolytic enzymes that degrade extracellular collagen and participate in vascular remodelling. In addition, the equilibrium between MMPs and their endogenous tissue inhibitors (TIMPs) is crucial for regulating the degradation of extracellular matrix, and its remodelling. MMPs play significant roles in many physiological conditions and are involved in several pathological states, including atherosclerosis.

Endothelial dysfunction and increased concentrations of biochemical markers of cardiovascular diseases have been observed in women with polycystic ovary syndrome (PCOS) [1–8]. Several MMPs [9–11], especially MMP-2 and MMP-9 [12–15], are involved in cardiovascular diseases including atherosclerosis, coronary artery disease and stroke [16–18]. Few studies to date, however, have investigated whether the levels of circulating MMPs and TIMPs are altered in women with PCOS [19–22], although we recently reported that women with PCOS have imbalances in circulating MMPs and

that these alterations were associated with excess circulating androgen in these women [22].

The first-line pharmacological therapy used in PCOS patients who do not want to conceive is an oral contraceptive (OC) because it effectively reduces androgen excess. To our knowledge, no study has evaluated whether the use of OC can alter plasma concentrations of MMPs in women with PCOS. We therefore investigated whether the administration to women with PCOS of an OC containing the anti-androgenic agent progestogen, thus reducing hyperandrogenism, could alter their MMP profiles.

Materials and Methods

Subjects and study protocol. This study was approved by the Institutional Review Board at the Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil, and each subject provided written informed consent. The present work was carried out in accordance with the ethics standards of the Helsinki Declaration.

We evaluated 20 women with PCOS who wanted hormonal contraception (OC-PCOS group), 20 ovulatory women who required hormonal contraception (OC-control group) and 20 ovulatory women who wanted a method of non-hormonal contraception (condoms or a copper intrauterine device) (non-OC-control group). All of these women had visited a basic health unit of the Faculty of Medicine of

Author for correspondence: Jose Eduardo Tanus-Santos, Department of Pharmacology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Av. Bandeirantes, 3900, 14049-900 Ribeirão Preto, SP, Brazil (fax +55 16 3633 2301, e-mails tanus@fmrp.usp.br; tanussantos@yahoo.com).

Ribeirão Preto, University of São Paulo (FMRP-USP), Brazil, between January 2008 and January 2010. Each woman with PCOS was matched by age and body mass index (BMI) to two ovulatory controls, 1 OC and 1 non-OC. Women were included if they were 18–35 years old, sexually active, wanted a method of contraception, had a BMI ≥ 18 and <30 kg/m² and had normal menstrual cycles (duration of between 24 and 32 days with individual variation of ± 3 days). The ovulatory women had pre-ovulatory symptoms, and those with PCOS were diagnosed using the Rotterdam criteria (2004) [23].

Women were excluded at screening if they had any clinical condition corresponding to category 3 or 4 of the World Health Organization medical eligibility criteria for OC use [24]. Other exclusion criteria included smoking, alcoholism, recreational drug use, any systemic disease (systemic arterial hypertension, diabetes mellitus, immune system diseases or thyroid diseases) except PCOS, current or previous (up to 2 months before the study) use of an oral, vaginal, monthly injectable or transdermal combined hormonal contraceptive or current or previous use (up to 6 months before the study) of a long-lasting hormonal contraceptive method (injectable, implant or intrauterine device). Women who had given birth within 12 weeks of study entry, those currently breastfeeding or who had stopped breastfeeding within 2 months of the screening visit and those with chronic and/or acute inflammatory processes were also excluded. All participants provided written informed consent, and the study was approved by the institutional review board of the FMRP-USP.

The OC used contained 2 mg of chlormadinone acetate (CMA) and 30 μ g of ethinylestradiol (EE) (Belara®; Janssen Cilag GmbH, Grünenthal, Germany). No participant in the OC-PCOS and OC-control groups was excluded from the study. Of the 20 participants in the non-OC-control group, 5 were excluded, including 3 who changed to a hormonal method and 2 who abandoned the protocol; thus, after 6 months, 15 women were evaluated (fig. 1).

Anthropometric measurements and laboratory tests. Weight, height, BMI and waist circumference (the lowest measurement between the iliac crest and the inferior margin of the last rib) were measured at screening. Blood samples were collected in the Gynecology Laboratory of the University Hospital of the FMRP-USP between 8:00 and 9:00 a.m. after at least 10 hr of fasting. Samples were collected from control women and women with PCOS and oligomenorrhoea during the follicular phase (third to seventh day of the cycle). PCOS patients with amenorrhoea were evaluated after pelvic ultrasonography showed no evidence of either a follicle ≥ 10 mm or a corpus luteum. Whole blood (20 mL) samples were divided into tubes without anticoagulant (for serum separation) and into plastic conical tubes (BD-Becton Dickinson, Plymouth, UK) with no vacuum and containing 3.2% sodium citrate, in a fixed proportion of nine parts whole blood to one part anticoagulant.

All blood samples were processed within 2 hr after collection, with serum samples stored at -80°C . Fasting serum glucose concentration

was determined by the oxidase method using a Konelab 60i analyser (Wiener Lab®, Rosario, Argentina). The concentrations of total cholesterol, HDL-cholesterol and triglycerides (TG) were measured enzymatically using a BT 3000 plus analyser (Wiener lab®); LDL-cholesterol concentrations were calculated according to the Friedewald formula [$\text{LDL-cholesterol} = \text{total cholesterol} - (\text{HDL-C} + \text{TG}/5)$] because none of the samples contained triglyceride concentrations >400 mg/dL [25]. Sex hormone-binding globulin (SHBG) and insulin were measured by chemoluminescence with the DPC Immulite® 2000 analyser (Diagnostic Products Corporation®, Los Angeles, CA, USA), and total testosterone was determined by radioimmunoassay using the Tri Carb 2100 TR scintillator (Packard® Instrument Company, IL, USA). The free androgen index (FAI) was calculated using the formula: $\text{total testosterone (nmol/L)} / \text{SHBG (nmol/L)} \times 100$ [26]. Insulin resistance was determined according to the homeostasis model assessment-insulin resistance (HOMA-IR) index, that is $\text{HOMA-IR} = \text{fasting serum glucose (mg/dL)} \times 0.05551 \times \text{fasting insulin (}\mu\text{U/mL)} / 22.5$ [27].

Measurement of plasma MMP-9, TIMP-1 and TIMP-2 concentrations.

Whole blood samples collected into anticoagulant were centrifuged at $120 \times g$ (700 rpm) in a Sorvall RC 3 centrifuge (Sorvall Kendro Laboratory Products GmbH, Langenselbold, Germany) at room temperature (mean 22°C ; range 18 – 24°C) for 15 min. Plasma was obtained by centrifuging the samples at $1600 \times g$ (2500 rpm) for 30 min. in a Universal 32 R centrifuge (Hettich Zentrifugen, Tuttlingen, Germany) at 4°C , and plasma aliquots were stored at -70°C until analysed. MMP-9, TIMP-1 and TIMP-2 concentrations were measured using commercially available enzyme-linked immunosorbent (ELISA) assay kits (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.

SDS-polyacrylamide gel electrophoresis (PAGE) gelatin zymography

of MMP-2. Gelatin zymography of MMP-2 from plasma samples was performed as described [28–30]. Briefly, plasma samples were subjected to electrophoresis on 7% SDS-PAGE co-polymerized with gelatin (1%). The gel was incubated for 1 hr at room temperature in 2% Triton X-100 solution and subsequently at 37°C for 16 hr in Tris-HCl buffer, pH 7.4, containing 10 mM CaCl_2 . The gels were stained with 0.05% Coomassie Brilliant Blue G-250 and destained with 30% methanol/10% acetic acid. Gelatinolytic activities were detected as unstained bands against the background of Coomassie blue-stained gelatin. Enzyme activity was assayed densitometrically using ImageJ version 1.42q (Wayne Rasband National Institutes of Health, USA). MMP-2 was identified as a 72 kDa band.

Statistical analysis. The mean TIMP-2 concentration in women with PCOS [22] indicated that the inclusion of at least 16 of these women would be necessary to observe a difference of one standard deviation between the pre- and post-treatment measurements, with a test power of 80% and an alpha of 5%.

All results were expressed as mean \pm standard error of the mean (S.E.M.). Non-normally distributed variables were compared using the Kruskal-Wallis test with post hoc Dunn's multiple comparison test, and normally distributed variables were compared by one-way ANOVA with post hoc Tukey's test. Comparisons within each group were assessed using Student's paired *t*-tests. Results were considered statistically significant when $p < 0.05$.

Results

The clinical characteristics of all participants are summarized in table 1. The mean ages of the OC-POS (25.1 ± 0.9 years),




Fig. 1. Study flow chart.

Table 1.
Clinical and laboratorial characteristics of study subjects.

	Non-OC-control group		OC-control group		OC-PCOS group	
	BL	6M	BL	6M	BL	6M
BMI (kg/m ²)	21.76 ± 0.68	22.17 ± 0.88	23.53 ± 0.75 ^T	24.03 ± 0.83	22.52 ± 0.96	22.70 ± 0.95
WC (cm)	69.53 ± 1.93	70.80 ± 2.11	73.58 ± 1.78	75.80 ± 2.21*	78.05 ± 2.24**	77.05 ± 2.17
SAP (mmHg)	109.20 ± 2.21	112.10 ± 2.05	113.30 ± 1.75	114.00 ± 1.52	113.90 ± 1.38	112.4 ± 1.97
DAP (mmHg)	75.07 ± 1.72	77.33 ± 1.58	77.95 ± 1.34	74.10 ± 1.53*	76.65 ± 1.47	74.50 ± 1.06
Ovarian volume (cm ³)	5.97 ± 0.20	5.87 ± 0.32	6.28 ± 0.32	5.25 ± 0.32	10.72 ± 0.59***	7.35 ± 0.50
TChol (mg/dL)	146.20 ± 6.73	148.30 ± 6.02	161.30 ± 6.93	161.00 ± 4.48	168.50 ± 5.63	188.90 ± 7.98*
TG (mg/dL)	56.93 ± 6.85	59.13 ± 7.72	75.55 ± 6.70	92.90 ± 6.24	75.55 ± 13.52	127.10 ± 16.07*
HDL (mg/dL)	46.53 ± 1.58	45.80 ± 1.63	49.50 ± 1.92	53.95 ± 1.99*	51.10 ± 1.80	61.40 ± 1.86*
LDL (mg/dL)	109.90 ± 6.43	84.47 ± 4.78*	97.85 ± 4.61	85.90 ± 2.75*	102.60 ± 4.45	101.10 ± 6.80
Glycaemia (mg/dL)	85.73 ± 1.91	82.53 ± 3.57	85.30 ± 1.39	75.45 ± 3.08*	87.00 ± 1.43	80.80 ± 1.63*
Insulin (μU/mL)	3.02 ± 0.43	2.28 ± 0.21	5.94 ± 0.88**	4.84 ± 0.75	5.24 ± 0.77**	6.02 ± 1.09
HOMA-IR	0.72 ± 0.14	0.62 ± 0.15	1.30 ± 0.19**	0.94 ± 0.15*	1.15 ± 0.17	1.26 ± 0.25
SHBG (nM)	59.87 ± 3.43	56.98 ± 5.19	58.99 ± 4.69	154.30 ± 8.83*	42.00 ± 3.83**	217.90 ± 25.28*
FAI (%)	2.90 ± 0.39	3.45 ± 0.37	3.57 ± 0.43	1.57 ± 0.28*	9.69 ± 2.61**	0.92 ± 1.66*

BMI, body mass index; WC, waist circumference; SAP, systolic arterial pressure; DAP, diastolic arterial pressure; TChol, total cholesterol; TG, tri-glycerides; HOMA-IR, homeostasis model assessment-insulin resistance; SHBG, sex hormone-binding globulin; FAI, free androgen index; CRP, C reactive protein; PCOS, polycystic ovary syndrome.

Values are the mean ± S.E.M.

^TSignificantly different by the Mann-Whitney U-test.

^{*}Significantly different by the unpaired *t*-test.

^{*}*p* < 0.05 versus baseline by two-tailed (baseline versus 6 months) paired *t*-test.

^{**}*p* < 0.05 versus baseline by two-tailed (baseline versus control-baseline) Kruskal-Wallis test with post hoc Dunn's multiple comparison test for normally distributed variables or by one-way ANOVA with post hoc Tukey's test for non-normally distributed variables.

^{***}Xxxxxxxx.

OC-control (24.0 ± 1.3 years) and non-OC-Control (27.5 ± 0.9 years) groups were similar (*p* = 0.09). Similarly BMI, systolic arterial pressure (SAP), diastolic arterial pressure (DAP) and concentrations of total cholesterol (TChol), triglycerides, HDL, LDL and fasting serum glucose were similar in the three groups (*p* > 0.05 each). However, patients with PCOS had higher ovarian volume, waist circumference and insulin (*p* < 0.05 each) than controls. Insulin concentrations (5.9 ± 0.8 IU/mL versus 3.0 ± 0.4 IU/mL, *p* < 0.05) and HOMA-IR score (1.3 ± 0.1 versus 0.7 ± 0.1, *p* < 0.05) were significantly higher in the OC-Control than in the non-OC-Control group, but remained within normal limits. In addition, FAI was significantly higher, and SHBG concentrations were significantly lower in the OC-PCOS than in the control groups (*p* < 0.01 each).

At baseline, the MMP-2 concentrations were similar among the three groups (*p* > 0.05), whereas TIMP-2 concentrations were significantly lower in the OC-PCOS than in the OC-Control group (161.0 ± 6.5 ng/mL versus 206.2 ± 11.2 ng/mL; *p* = 0.01; fig. 2B). As expected, the baseline MMP-2/TIMP-2 ratio was significantly higher in the OC-PCOS group than in the OC-Control group (0.009 ± 0.0005 ng/mL versus 0.007 ± 0.0004 ng/mL; *p* = 0.005; fig. 2C). However, MMP-9 and TIMP-1 concentrations and the MMP-9/TIMP-1 ratio were similar in the three groups (*p* > 0.05 each) (fig. 3).

Treatment with OC increased waist circumference and HDL concentration, and reduced DAP, LDL and serum glucose concentrations in the OC-Control group. In the OC-PCOS group, 6 months of OC increased TChol, triglyceride and HDL concentrations, while reducing serum glucose concentrations and FAI

Treatment with OC for 6 months significantly reduced MMP-2 concentrations in the OC-control group, from 1.44 ± 0.11 arbitrary units at baseline to 1.22 ± 0.07 arbitrary units after 6 months (*p* = 0.01), and in the OC-PCOS group, from 1.43 ± 0.08 arbitrary units at baseline to 1.25 ± 0.09 arbitrary units after 6 months (*p* = 0.007) (fig. 2A). Moreover, OC treatment of women in the OC-Control group significantly reduced TIMP-1 (448.0 ± 66.3 ng/mL versus 349.0 ± 40.9 ng/mL; *p* = 0.009; fig. 3B) and TIMP-2 (206.2 ± 11.3 ng/mL versus 181.7 ± 10.4 ng/mL; *p* = 0.03; fig. 2B) concentrations after 6 months. However, OC treatment did not alter MMP-9 concentrations or the MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios after 6 months (*p* > 0.05 each).

Discussion

We have shown here for the first time that the long-term treatment with an OC containing chlormadinone acetate plus combined with ethinylestradiol reduced plasma MMP-2 concentrations levels in both PCOS and healthy women.

Hyperandrogenism, a key component of PCOS, is often associated with increased metabolic and cardiovascular risks in women with PCOS. According to the Rotterdam criteria, only one of the four phenotypes of PCOS does not require clinical hyperandrogenism for diagnosis [31]. Women with the three phenotypes that include hyperandrogenism have higher levels of cardiovascular risk markers [32], such as increased carotid intima-media thickness [33]. Reducing circulating androgen concentrations may therefore decrease parameters associated with cardiovascular risk.

4

VALÉRIA A. GOMES ET AL.




Fig. 2. Effect of oral contraceptive on plasma concentrations of (A) MMP-2 and (B) TIMP-2, and on (C) the MMP-2/TIMP-2 ratio in non-OC-Controls (N = 15), OC-Controls (N = 20) and OC-PCOS (N = 20) women after 6 months. * $p < 0.05$ versus baseline by two-tailed (baseline versus baseline) unpaired *t*-test. * $p < 0.05$ versus baseline by two-tailed (baseline versus 6 months) paired *t*-test.

Oral contraceptives is the medical treatment most widely used to reduce hyperandrogenism in women with PCOS. As expected, we found that an anti-androgenic OC containing ethinylestradiol and chlormadinone acetate increased total cholesterol, triglyceride and HDL concentrations in women with PCOS, but not in women without PCOS. OC use reduced serum glucose concentrations in both groups. All the alterations in biochemical metabolism we observed were within normal limits and were in agreement with results of previous studies [34, 35].




Fig. 3. Effect of oral contraceptive on plasma concentrations of (A) MMP-9 and (B) TIMP-1, and on (C) the MMP-9/TIMP-1 ratio in non-OC-Controls (N = 15), OC-Controls (N = 20) and OC-PCOS (N = 20) women after 6 months. * $p < 0.05$ versus baseline by two-tailed (baseline versus baseline) unpaired *t*-test. * $p < 0.05$ versus baseline by two-tailed (baseline versus 6 months) paired *t*-test.

We found that use of an anti-androgenic OC containing ethinylestradiol and chlormadinone acetate reduced plasma MMP-2 concentrations in women with and without PCOS. These findings suggest that the reduction of free testosterone induced by this anti-androgenic contraceptive may be involved in the reduction in MMP-2 concentrations we observed. While this is the first study showing such effects for OC, there is growing experimental [36–39] and clinical [40] evidence that some cardiovascular drugs may affect MMP levels, we have not included

patients taking any other medications in the present study and therefore, our findings reflect the effects exerted by OC only.

Few studies have evaluated the relationship between MMP-2 and testosterone. Androgen has been shown to stimulate MMP-2 expression via androgen receptor transactivation in human prostate cancer LNCaP cells [41], and two androgen response elements involved in androgen-induced MMP-2 expression have been identified [42]. Although testosterone reduced MMP-2 activity in the ovaries of a rat model of PCOS but not in control rats [43], testosterone had no effect on the MMP-2 gene and protein expression in human aortic smooth muscle cells [44], but in this study, the testosterone concentrations were based on the average level of free testosterone in an adult male. Additional studies are necessary to confirm these findings and to determine the mechanisms linking MMP-2 and testosterone interaction.

Matrix metalloproteinases clearly play a role in cardiovascular remodelling, especially MMP-2 [45–48]. In fact, imbalanced MMPs have been shown in many conditions associated with increased cardiovascular risk [49–52], and it is possible that altered circulating MMP levels contribute to this increased risk. Consequently, the ability of an anti-androgenic OC to reduce MMP-2 concentrations in women with PCOS may reduce their cardiovascular risk.

Alterations in MMP and TIMP concentrations have been observed in women with PCOS [19, 21, 22]. Moreover, we reported that hyperandrogenism, one of the main characteristics of PCOS, was an independent predictor of reduced TIMP-2 concentrations and increased MMP-9/TIMP-1 ratios [22]. We have shown here that the reduction of hyperandrogenism, promoted by treatment with OC, reduced MMP-2 levels in women with PCOS.

This study had several limitations. Circulating MMPs and TIMPs may be released into the bloodstream by various tissue sources, including cardiac, ovarian and vascular tissues, as well as peripheral blood neutrophils. Therefore, our results should be interpreted with caution because plasma MMP and TIMP levels may not reflect local cardiovascular tissue concentrations. Although OC reduced MMP-2 concentrations in both women with PCOS and healthy controls, it is not known whether the cardiovascular risk of these women will be affected in the future. In addition, we have not studied the effects of other therapies for PCOS on MMPs.

In conclusion, we showed that an OC containing 2 mg chlormadinone acetate and 30 µg of ethinylestradiol with anti-androgenic effects reduced plasma concentrations of MMP-2 in women with PCOS, suggesting that this may be an important benefit of OCs in this group.

Acknowledgements

This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo and Conselho Nacional de Desenvolvimento Científico e Tecnológico.

References

- 1 Diamanti-Kandaraki E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Paterakis T, *et al.* Inflammatory and endothelial markers in women with polycystic ovary syndrome. *Eur J Clin Invest* 2006;36:691–7.
- 2 Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S, *et al.* Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. *J Clin Endocrinol Metab* 2008;93:82–90.
- 3 Gonzalez F, Rote NS, Minium J, Kirwan JP. Evidence of proatherogenic inflammation in polycystic ovary syndrome. *Metabolism* 2009;58:954–62.
- 4 Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. *Hum Reprod* 2005;20:2409–13.
- 5 Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, *et al.* Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2004;89:4588–93.
- 6 Soares GM, Vieira CS, Martins WP, Franceschini SA, dos Reis RM, Silva de Sa MF, *et al.* Increased arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS) without comorbidities: one more characteristic inherent to the syndrome? *Clin Endocrinol (Oxf)* 2009;71:406–11.
- 7 Talbot EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsburg KE, *et al.* Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. *Arterioscler Thromb Vasc Biol* 2000;20:2414–21.
- 8 Talbot EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2004;89:5454–61.
- 9 Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL, *et al.* Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. *Atherosclerosis* 2008;198:320–31.
- 10 Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. *Circ Res* 2002;90:251–62.
- 11 Liapis CD, Paraskevas KI. The pivotal role of matrix metalloproteinases in the development of human abdominal aortic aneurysms. *Vasc Med* 2003;8:267–71.
- 12 Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P, *et al.* Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. *Eur J Clin Invest* 2003;33:648–56.
- 13 Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, *et al.* Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. *Stroke* 2000;31:40–7.
- 14 Yasmin ???, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K, *et al.* Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. *Arterioscler Thromb Vasc Biol* 2005;25:372.
- 15 Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, *et al.* Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. *Circulation* 2003;107:1579–85.
- 16 Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? *Circ Res* 2001;89:201–10.
- 17 Fatar M, Stroick M, Griebel M, Hennerici M. Matrix metalloproteinases in cerebrovascular diseases. *Cerebrovasc Dis* 2005;20:141–51.
- 18 van den Borne SW, Cleutjens JP, Hancmaaijer R, Creemers EE, Smits JF, Daemen MJ, *et al.* Increased matrix metalloproteinase-8

- and -9 activity in patients with infarct rupture after myocardial infarction. *Cardiovasc Pathol* 2009;18:37-43.
- 19 Liu B, Cai LY, Lv HM, Xia L, Zhang YJ, Zhang HX, *et al.* Raised serum levels of matrix metalloproteinase-9 in women with polycystic ovary syndrome and its association with insulin-like growth factor binding protein-1. *Gynecol Endocrinol* 2008;24:285-8.
 - 20 Diamanti-Kandarakis E, Livadas S, Kandarakis SA, Margeli A, Pappasotiou I. Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism? *Eur J Endocrinol* 2008;158:525-31.
 - 21 Lewandowski KC, Komorowski J, O'Callaghan CJ, Tan BK, Chen J, Prelevic GM, *et al.* Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. *J Clin Endocrinol Metab* 2006;91:1173-7.
 - 22 Gomes VA, Vieira CS, Jacob-Ferreira AL, Belo VA, Soares GM, Fernandes JB, *et al.* Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome. *Mol Cell Biochem* 2011;353:251-7.
 - 23 ?????? ?????? Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) *Hum Reprod* 2004;19:41-7.
 - 24 Organization WH. Medical Eligibility Criteria for Contraceptive Use. Organization WH, editor, ??????, 2009.
 - 25 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972;18:499-502.
 - 26 Mathur RS, Moody LO, Landgrebe S, Williamson HO. Plasma androgens and sex hormone-binding globulin in the evaluation of hirsute females. *Fertil Steril* 1981;35:29-35.
 - 27 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28:412-9.
 - 28 Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos JE. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. *Clin Biochem* 2005;38:410-4.
 - 29 Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. *Anal Biochem* 2005;344:147-9.
 - 30 Gerlach RF, Demacq C, Jung K, Tanus-Santos JE. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. *Clin Biochem* 2007;40:119-23.
 - 31 Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. *Lancet* 2007;370:685-97.
 - 32 Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. *J Clin Endocrinol Metab* 2005;90:2545-9.
 - 33 Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF. Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. *Hum Reprod* 2007;22:3197-203.
 - 34 Vrbikova J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. *Hum Reprod Update* 2005;11:277-91.
 - 35 Guido M, Romualdi D, Campagna G, Ricciardi L, Bompiani A, Lanzone A. Ethinylestradiol-chlormadinone acetate combination for the treatment of hirsutism and hormonal alterations of normal-weight women with polycystic ovary syndrome: evaluation of the metabolic impact. *Reprod Sci* 2010;17:767-75.
 - 36 Marcal DM, Rizzi E, Martins-Oliveira A, Ceron CS, Guimaraes DA, Gerlach RF, *et al.* Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension. *Naunyn Schmiedeberg Arch Pharmacol* 2011;383:35-44.
 - 37 Martinez ML, Castro MM, Rizzi E, Fernandes K, Demacq C, Bendhack LM, *et al.* Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. *Eur J Pharmacol* 2008;591:224-30.
 - 38 Ceron CS, Castro MM, Rizzi E, Montenegro MF, Fontana V, Salgado MC, *et al.* Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. *Br J Pharmacol* 2010;160:77-87.
 - 39 Izidoro-Toledo TC, Guimaraes DA, Belo VA, Gerlach RF, Tanus-Santos JE. Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. *Naunyn Schmiedeberg Arch Pharmacol* 2011;383:547-54.
 - 40 Martinez ML, Lopes LF, Codho EB, Nobre F, Rocha JB, Gerlach RF, *et al.* Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. *J Cardiovasc Pharmacol* 2006;47:117-22.
 - 41 Liao X, Thrasher JB, Pelling J, Holzbeierlein J, Sang QX, Li B. Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. *Endocrinology* 2003;144:1656-63.
 - 42 Li BY, Liao XB, Fujito A, Thrasher JB, Shen FY, Xu PY. Dual androgen-response elements mediate androgen regulation of MMP-2 expression in prostate cancer cells. *Asian J Androl* 2007;9:41-50.
 - 43 Henmi H, Endo T, Nagasawa K, Hayashi T, Chida M, Akutagawa N, *et al.* Lysyl oxidase and MMP-2 expression in dehydroepiandrosterone-induced polycystic ovary in rats. *Biol Reprod* 2001;64:157-62.
 - 44 Natoli AK, Medley TL, Ahimastos AA, Drew BG, Thearle DJ, Dille RJ, *et al.* Sex steroids modulate human aortic smooth muscle cell matrix protein deposition and matrix metalloproteinase expression. *Hypertension* 2005;46:129-34.
 - 45 Castro MM, Rizzi E, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. *Matrix Biol* 2010;29:194-201.
 - 46 Guimaraes DA, Rizzi E, Ceron CS, Oliveira AM, Oliveira DM, Castro MM, *et al.* Doxycycline dose-dependently inhibits MMP-2-mediated vascular changes in 2K1C hypertension. *Basic Clin Pharmacol Toxicol* 2011;108:318-25.
 - 47 Rizzi E, Castro MM, Prado CM, Silva CA, Fazan R Jr, Rossi MA, *et al.* Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. *J Card Fail* 2010;16:599-608.
 - 48 Lacchini R, Jacob-Ferreira AL, Luizon MR, Gasparini S, Ferreira-Sae MC, Schreiber R, *et al.* Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodeling in hypertensive patients. *J Hum Hypertens* 2012;26:171-7.
 - 49 Belo VA, Souza-Costa DC, Luizon MR, Lanna CM, Carneiro PC, Izidoro-Toledo TC, *et al.* Matrix metalloproteinase-9 genetic variations affect MMP-9 levels in obese children. *Int J Obes (Lond)* 2012;36:69-75.
 - 50 Goncalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, Marcaccini AM, *et al.* Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. *Clin Chim Acta* 2009;403:173-7.
 - 51 Marson BP, Lacchini R, Belo V, Dickel S, Da Costa BP, Poli de Figueiredo CE, *et al.* Matrix Metalloproteinase (MMP)-2 Genetic Variants Modify the Circulating MMP-2 Levels in End-Stage Kidney Disease. *Am J Nephrol* 2012;35:209-15.
 - 52 Palei AC, Sandrim VC, Amaral LM, Machado JS, Cavalli RC, Duarte G, *et al.* Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy. *Exp Mol Pathol* 2012;92:217-21.

DISCUSSÃO

A SOP além de ser uma endocrinopatia frequente entre as mulheres com idade reprodutiva está frequentemente associada às comorbidades que são sabidamente fatores de risco cardiovascular. Deste modo, acredita-se que mulheres com SOP estejam predispostas a desenvolver DCV precocemente. Assim, já que as MMPs estão implicadas a doenças cardiovasculares, torna-se pertinente avaliar as concentrações plasmáticas de MMPs e TIMPs em pacientes com SOP.

Nossos achados iniciais são que: (1) as pacientes com SOP têm um desequilíbrio entre MMPs e TIMPs, incluindo concentrações mais baixas de TIMP-2 e aumento nas razões MMP-2/TIMP-2 e MMP-9/TIMP-1 em comparação com indivíduos saudáveis e (2) a testosterona foi relacionada negativamente com os níveis plasmáticos de TIMP-2 e positivamente com a razão MMP-9/TIMP-1.

Esse é primeiro estudo que mostra uma associação entre a testosterona e os níveis de TIMP-2 e com a razão MMP-9/TIMP-1, sugerindo que o hiperandrogenismo, observado na maioria das mulheres com SOP, pode ser um fator contribuinte para o risco cardiovascular, devido à participação dessas enzimas e seus inibidores teciduais em DCV.

Inicialmente, o principal achado desse trabalho é que as mulheres com SOP possuem um desequilíbrio entre MMPs e TIMPs. Nossos resultados mostram um aumento das razões MMP-2/TIMP-2 e MMP-9/TIMP-1 em mulheres com SOP quando comparadas com mulheres saudáveis. Esses resultados são importantes porque é, justamente, o equilíbrio crítico entre MMPs e TIMPs que determina a degradação da matriz extracelular.

DISCUSSÃO

Atualmente, tem-se sugerido que a razões entre MMPs/TIMPs sejam melhores marcadores do que as MMPs e os TIMPs isoladamente. Pois, alterações no equilíbrio entre esses dois parâmetros, favorecendo o aumento da degradação da matriz, podem resultar em alterações estruturais e funcionais cardíacas associadas à DCV como, por exemplo, a hipertensão [26,57].

Além disso, quando comparamos a concentração plasmática de TIMP-2 entre as mulheres saudáveis e as mulheres com SOP, as últimas tiveram valores significativamente inferiores. A atividade das MMPs é regulada principalmente pela interação dessas enzimas com os TIMPs. Até o momento, existem quatro TIMPs conhecidos até o momento e eles são responsáveis por inibir mais de 25 MMPs. Contudo, embora os TIMPs possam inibir qualquer MMP, os TIMP-1 e TIMP-2 são os principais inibidores da MMP-9 e da MMP-2, respectivamente [58].

É importante salientar que as ações dos TIMPs não se limitam a inibir a ação proteolítica das MMPs. Os TIMPs participam na regulação da migração celular, proliferação e apoptose. Além disso, estudos também têm demonstrado que os TIMPs podem estimular a produção de colágeno por fibroblastos cardíacos [59,24,60-62].

Recentemente, Kandalam *et al* [59], demonstraram que o TIMP-2 exerce papel chave na regulação das respostas cardíacas ao infarto do miocárdio. Portanto, é possível considerar que o TIMP-2 possa contribuir para as alterações cardiovasculares em mulheres com PCOS. Além disso, o TIMP-2, quando está em altas concentrações inibe a MMP-2. Por outro lado, quando esse inibidor está em baixas concentrações participa da ativação da MMP-2 [63,64]. A ativação da pró-MMP-2 pela MT1-MMP requer a formação de um complexo trimolecular entre a

DISCUSSÃO

pró-MMP-2, MT1-MMP e o TIMP-2, em que o domínio C-terminal do TIMP-2 liga-se ao domínio hemopexina da pró-MMP-2 e, o domínio N-terminal desse inibidor se liga ao sítio ativo da MT1-MMP. Uma vez formado o complexo, a MT1-MMP adjacente ao complexo cliva o pró-domínio da MMP-2, tornando-a ativa [64,63].

Portanto, as baixas concentrações plasmáticas de TIMP-2 em mulheres com SOP é um achado importante, pois além de favorecer o desequilíbrio da razão entre MMP-2/TIMP-2, que pode induzir ao aumento da degradação da matriz extracelular como citado anteriormente, também pode favorecer a ativação da MMP-2.

Sabe-se, ainda, que essa MMP exerce importante papel no remodelamento cardiovascular envolvido no mecanismo patológico de diversas DCVs. Um trabalho recente relatou a presença de MMP-2 no interior do cardiomiócito, região em que essa enzima atua sobre os substratos intracelulares, entre eles a troponina I [65].

Além da troponina I, já se descobriram outros substratos não relacionadas à matriz extracelular para a MMP-2. Estes substratos incluem a big endotelina-1 [66], o peptídeo relacionado ao gene da calcitonina (CGRP) [67] e a adrenomedulina (AM) [68]. Ao clivar esses substratos, a MMP-2 gera metabólitos com ações vasoconstritoras potentes.

Recentes estudos sugeriram a participação da MMP-8 em algumas DCVs, entre elas a aterosclerose [53]. As concentrações plasmáticas da MMP-8 foram positivamente associadas à presença e severidade de doença arterial coronariana [53,69]. O Aumento nos níveis plasmáticos de MMP-8 já foram relatados em pacientes com síndrome metabólica. O presente estudo foi o primeiro a propor a

DISCUSSÃO

avaliação das concentrações plasmáticas dessa MMP em pacientes com ovário policístico. Os nossos resultados não indicam a participação dessa MMP na SOP, já que não encontramos diferença significativa nos níveis de MMP-8 nas mulheres com SOP quando comparadas com mulheres saudáveis.

O aumento das razões MMP-2/TIMP-2 e MMP-9/TIMP-1 observados nesse estudo corroboram com os demais estudos que avaliaram os mesmos parâmetros nas pacientes com SOP [70,71]. Embora as razões MMPs/TIMPs estejam aumentadas nas pacientes com SOP, a elevação dos níveis de MMP-9 e a redução dos níveis de TIMP-1 que foram observados nessas pacientes, não foram estatisticamente significativos quando comparados com indivíduos saudáveis. Apesar disso, essas alterações contribuíram para o aumento da razão MMP-9/TIMP-1 observado no grupo SOP. No entanto, esses achados estão em contraste com os estudos anteriores [70,72], que encontraram um aumento nas concentrações séricas de MMP-2 [72] e de MMP-9 [72,70] em pacientes com SOP quando comparadas com pacientes saudáveis. Por outro lado, no estudo de Lewandowski *et al* [72], o aumento dos níveis de MMP-9 e MMP-2 em mulheres com PCOS pode ser devido à obesidade presente no grupo SOP.

Os resultados contrastantes entre o presente trabalho e os anteriores podem ser parcialmente explicados pelas diferenças entre os estudos. Uma das diferenças diz respeito ao tipo de método empregado nos trabalhos para determinar os níveis plasmáticos de MMP-2. No presente estudo utilizamos zimografia já, no trabalho citado anteriormente o ensaio utilizado foi o Elisa. Outra diferença entre os estudos é o tipo de amostra empregada para determinar os níveis plasmáticos de MMPs e TIMPs. Nos trabalhos anteriores foram utilizados

DISCUSSÃO

soro ao invés de plasma. Diferenças a respeito do tipo de amostra utilizada para determinar os níveis plasmáticos de MMPs já foram evidenciadas em estudos anteriores. Nesses trabalhos foi observado que amostras de soro não são apropriadas para a determinação de MMPs [73,74], visto que no soro, durante a coagulação sanguínea, ocorre a liberação de diversas proteases que podem ativar a MMP-9. Além disso, também ocorre a liberação de MMPs por plaquetas e/ou leucócitos durante a ativação plaquetária, resultando em níveis artificialmente aumentados quando comparados com os níveis plasmáticos [73-75].

Além dessas diferenças, o tamanho amostral dos estudos anteriores é inferior ao do presente estudo, o que pode, em parte, explicar a divergência entre os estudos. Além disso, a presença e severidade das comorbidades presentes nas mulheres com SOP avaliadas podem ter impacto sobre os níveis circulantes das MMPs.

Sabe-se que é frequente a presença de fatores de risco cardiovascular, como resistência à insulina e obesidade em mulheres com SOP quando comparadas a mulheres saudáveis. Um dos critérios de inclusão no estudo foi o IMC $<30 \text{ kg/m}^2$. Apesar disso, na primeira parte do estudo, as mulheres do grupo SOP apresentaram IMC e HOMA-IR significativamente maiores do que as controles. A medida da circunferência abdominal, a média da pressão sistólica e os níveis de insulina também foram estatisticamente diferentes, entretanto os valores estão no limiar normal.

Nós também avaliamos dois marcadores inflamatórios, a interleucina 6 e a proteína C reativa (CRP), e ambos não foram diferentes entre os dois grupos analisados. Vários trabalhos já se propuseram estudar esses dois marcadores e

DISCUSSÃO

os resultados obtidos foram conflitantes, pois alguns deles sugerem o aumento dos níveis em mulheres com SOP quando comparadas a indivíduos saudáveis, enquanto que outros não observaram essas diferenças. Uma meta-análise realizada recentemente sugere que as mulheres com SOP possuem níveis elevados de CRP quando comparadas a mulheres saudáveis. Porém, não foi constatado diferenças nas concentrações de interleucina 6 entre mulheres com SOP e mulheres saudáveis [76].

Para avaliar a influência de algumas variáveis comumente observadas na SOP (IMC, HOMA e testosterona), assim como a própria SOP sobre as concentrações plasmáticas de MMPs, TIMPs e das razões entre MMPs e TIMPs, realizamos uma análise por regressão linear múltipla. Apesar de alguns trabalhos mostrarem aumento dos níveis de MMPs na obesidade [77], inclusive em mulheres obesas [78,79], o IMC não foi preditor de nenhuma das MMPs e nem dos TIMPs estudados no presente estudo. Contudo, a diferença significativa do IMC entre as pacientes com SOP e as controles saudáveis deve-se ao sobrepeso apresentado por algumas pacientes do primeiro grupo e não a obesidade.

O índice HOMA também não foi preditor de nenhum dos parâmetros avaliados, mesmo tendo estudos que mostram que a hiperinsulinemia aumenta tanto a MMP-2 (em aproximadamente 6 vezes) quanto a MMP-9 (em aproximadamente em 13 vezes) [80,81]. Embora, a média do índice HOMA tenha sido maior nas SOPs, os valores desse parâmetro estão na faixa de normalidade. Todavia, esses achados não são suficientes para eliminar completamente a possibilidade de que a resistência à insulina e/ou à obesidade possam contribuir para o desequilíbrio das razões entre MMPs e TIMPs observado na SOP.

DISCUSSÃO

Um dos principais achados desse estudo é que a testosterona foi um preditor independente dos níveis de TIMP-2 e da razão MMP-9/TIMP-1, sendo um preditor negativo para o TIMP-2 e positivo para a razão MMP-9/TIMP-1. Este é o primeiro estudo mostrando a evidência dessas associações. Esse resultado corrobora com outro resultado do mesmo estudo, em que encontramos uma correlação negativa entre as concentrações plasmáticas de TIMP-2 e os níveis de testosterona e uma correlação positiva entre a razão MMP-9/TIMP-1, novamente com a testosterona.

Uma das principais características da SOP é a presença de hiperandrogenismo clínico e/ou laboratorial. Os nossos achados também sugerem a participação da testosterona no aumento dos fatores de risco cardiovascular nas mulheres com SOP, que é aqui representado pelo desequilíbrio da relação entre MMPs e TIMPs e com a redução plasmática de TIMP-2 observada nessas pacientes.

Os critérios de Rotterdam para o diagnóstico da SOP abrange quatro fenótipos, e somente um deles não necessita do hiperandrogenismo para o diagnóstico [82]. Logo, o hiperandrogenismo, que é observado em aproximadamente 60-80% das pacientes com SOP, é uma das características fundamentais dessa síndrome. Alguns estudos já se propuseram a avaliar quais fenótipos representam maiores e menores riscos cardiovasculares. Um deles observou que o único fenotipo que não possui o hiperandrogenismo foi o que apresentou características endócrinas e metabólicas mais leves [83]. Já, as mulheres com os três fenótipos que incluem hiperandrogenismo possuem níveis mais elevados de marcadores de risco cardiovascular (41, 42), como por exemplo,

o aumento da espessura da camada íntima - média da carótida observada nas mulheres com SOP está correlacionada com o hiperandrogenismo [84,13].

Apesar desses achados, sugerindo o envolvimento dos andrógenos endógenos no desenvolvimento de DCV, os poucos estudos com mulheres sem SOP, que examinaram a associação entre andrógenos endógenos e o desenvolvimento de DCV não observaram participação importante dos andrógenos nesse processo [85]. Entretanto, recentemente um grande estudo associou as altas concentrações de testosterona com os marcadores de aterosclerose [86].

A disfunção endotelial também tem sido relacionada com o aumento da testosterona livre [87]. Além disso, as concentrações de androgênios no soro foram relatadas como preditor da pressão sanguínea em mulheres jovens sem SOP [88]. A testosterona livre, por sua vez, foi caracterizada como preditor nas mulheres jovens com SOP [89]. Embora, nenhum estudo tenha provado a relação causa-efeito entre a testosterona e a DCV em um trabalho com modelo experimental, a administração de testosterona em primatas fêmeas foi associado ao aumento da aterogênese [90].

Contudo, apesar de várias evidências, tanto bioquímicas quanto clínicas, ainda não se sabe, até o presente momento, qual o papel preciso da testosterona endógena no desenvolvimento da aterosclerose e de outras DCVs. Nossos resultados sugerem uma possível participação do hiperandrogenismo no desequilíbrio entre MMPs e TIMPs observado nas mulheres com SOP. Este panorama de alteração do equilíbrio entre MMPs e TIMPs, conseqüentemente, pode favorecer um aumento do risco de desenvolvimento de doenças

cardiovasculares neste grupo de mulheres. Portanto, intervenções farmacológicas, focando a redução do hiperandrogenismo e/ou das MMPs podem ser benéficas nas pacientes com SOP.

Na primeira parte do estudo não foi observado um aumento nas concentrações plasmáticas de MMP-2 e MMP-9 em mulheres com SOP. Entretanto, as relações MMP-2/TIMP-2 e MMP-9/TIMP-1 estavam aumentadas, o que poderia predispor-las a um risco cardiovascular maior. De acordo com os nossos achados, a testosterona poderia ser um preditor do desequilíbrio entre MMPs e TIMPs observado na SOP.

A droga de primeira escolha para a redução do hiperandrogenismo em mulheres com SOP que não desejam a contracepção é o anticoncepcional oral (ACO). Dessa maneira, na segunda parte do estudo foi investigado se a redução do hiperandrogenismo com a administração de ACO com propriedades antiandrogênicas em mulheres com SOP é acompanhado da redução dos níveis de MMPs nessas mulheres.

Acredita-se que o hiperandrogenismo presente na SOP seja de origem multifatorial, onde o ovário possui a maior parcela de contribuição tendo portanto uma participação primordial. Em menor proporção temos a contribuição das adrenais e por último do tecido adiposo.

Diversas drogas que visam bloquear a produção ovariana de andrógenos ou sua ação periférica são utilizadas no tratamento do hiperandrogenismo. Uma das drogas mais utilizadas em mulheres que desejam a contracepção é o ACO. A redução do hiperandrogenismo pelo ACO é uma ação conjunta dos dois componentes presentes na sua formulação. No nosso caso, o ACO utilizado é

DISCUSSÃO

composto por etinilestradiol e acetato de clormadinona. O etinilestradiol aumenta os níveis circulantes de hormônio sexual ligado à globulina (SHBG) que, por sua vez, reduz a concentração de testosterona livre circulante, uma vez que o SHBG liga-se preferencialmente à testosterona. O componente progestágeno inibe a 5 α -redutase e atua como antagonista no receptor de androgênios [91]. Além disso, o ACO também diminui a produção de androgênio pela adrenal, através de um mecanismo ainda pouco esclarecido. Mas, possivelmente, seja devido a uma diminuição na produção hormonal de adrenocorticotropina (ACTH).

O principal achado desse trabalho foi a redução dos níveis plasmáticos da MMP-2 depois de seis meses de tratamento com o ACO, contendo etinilestradiol e acetato de clormadinona em mulheres com SOP. Vale ressaltar, que nenhum trabalho prévio avaliou o perfil das MMPs nas mulheres com SOP após o tratamento com ACO. Estas descobertas sugerem que a redução da testosterona livre induzida por esse contraceptivo antiandrogênico pode estar envolvida na diminuição da MMP-2 plasmática observada no presente estudo.

O aumento da expressão e atividade da MMP-2 já foi demonstrado diversas vezes em DCV [34,39,45,20], assim como o aumento plasmático. Além disso, essa MMP está associada às alterações morfológicas arteriais em modelo experimental de hipertensão [37,38] e de aterosclerose [20]. Do mesmo modo, a MMP-2 pode induzir ações vasoconstritoras, por alterar as concentrações teciduais de alguns peptídeos vasoativos, como citado anteriormente. Portanto, é possível que o aumento da atividade da MMP-2 possa contribuir para uma disfunção endotelial e para o aumento da resistência vascular periférica. Estes

DISCUSSÃO

estudos também propõem a participação da MMP-2 no remodelamento vascular relacionado à DCV. Portanto, medidas que visam a redução de marcadores que tenham envolvimento com a instalação e progressão de DCV nas mulheres com SOP é relevante. Porém, poucos estudos avaliaram a relação entre a MMP-2 e a testosterona para sugerirmos um suposto mecanismo para a redução da MMP-2 por consequência da redução da testosterona disponível.

Em um estudo com células LNCaP demonstrou-se que o androgênio regula a expressão de MMP-2 via receptor de androgênios de maneira dependente da PI3K [92], sugerindo que o androgênio possa ser um possível modulador da MMP-2. Recentemente, identificou-se que dois elementos de resposta ao androgênio estão envolvidos na indução da MMP-2 pelo androgênio [93]. Contudo, em um segundo estudo com células musculares lisas de humanos, a testosterona não teve nenhum efeito sobre a expressão do gene da MMP-2 [94].

De modo contrário aos demais achados, Henmi *et al* [95] observaram redução da atividade da MMP-2 no ovário de ratas estimuladas com dehidroepiandrosterona (DHEA) durante sete e quinze dias. Portanto, esses resultados sugerem que a regulação da MMP-2 é dependente de estímulo específico e do tipo celular. Mesmo assim, são necessários estudos adicionais para determinar os mecanismos de interação entre a MMP-2 e a testosterona.

O tratamento com ACO não alterou significativamente os níveis de MMP-9, TIMP-1 e TIMP-2 nas mulheres com SOP. Também não foram observadas modificações relevantes nas razões MMP-2/TIMP-2 e MMP-9/TIMP-1. Uma limitação importante dos nossos estudos é que não conseguimos delimitar a principal fonte das MMPs e TIMPs circulantes, pois os dois marcadores podem ser

liberados na corrente sanguínea por diferentes fontes teciduais, visto que numerosos tipos celulares podem expressar essas enzimas, incluindo células vasculares, cardiomiócitos, células endoteliais, células musculares lisas, fibroblastos e neutrófilos. Desse modo, os resultados dos nossos estudos devem ser interpretados com prudência, visto que os níveis plasmáticos, tanto de MMPs quanto de TIMPs podem não refletir as concentrações plasmáticas do sistema cardiovascular.

Ademais, mesmo não sendo o foco principal do nosso trabalho, as concentrações plasmáticas de alguns marcadores de risco cardiovascular que refletem disfunção metabólica foram avaliados, uma vez que os ACOs possuem alguns efeitos conhecidos sobre o metabolismo lipídico. Como esperado, o uso do ACO durante 6 meses aumentou as concentrações plasmáticas do colesterol total, dos triglicérides e do HDL e reduziu os níveis de glicose. Esses achados, além de estarem de acordo com estudos anteriores, [91,96,97] também estão dentro dos limites desejáveis.

As principais conclusões do estudo mostram que: 1) em comparação com indivíduos saudáveis, as pacientes com SOP têm um desequilíbrio entre MMPs e TIMPs, incluindo menores concentrações de TIMP-2 e aumento das razões MMP-2/TIMP-2 e MMP-9/TIMP-1; 2) o TIMP-2 foi negativamente relacionado aos níveis de testosterona, enquanto que a razão MMP-9/TIMP-1 foi positivamente relacionada aos níveis de testosterona e 3) o uso do anticoncepcional oral, contendo etinilestradiol e acetato de clomardinona por 6 meses reduz os níveis plasmáticos de MMP-2, o que sugere que esse tratamento pode reduzir o risco de futuro evento cardiovascular neste grupo de mulheres.

CONCLUSÃO GERAL

CONCLUSÕES

Nossos dados demonstram que as razões MMP-2/TIMP-2 e MMP-9/TIMP-1 estão aumentadas nas mulheres com SOP e que os níveis plasmáticos de TIMP-2 estão reduzidos nessas pacientes, quando comparadas às controles. Além disso, a testosterona total foi um preditor independente dos níveis de TIMP-2 e da razão MMP-9/TIMP-1. Juntos, esses resultados revelam que o hiperandrogenismo, característica-chave em mulheres com SOP, pode contribuir para o desequilíbrio observado entre MMPs e TIMPs nas pacientes. Na segunda etapa do nosso estudo, observamos que o uso do anticoncepcional oral (2 mg de acetato de clormadinona e 0,03 mg de etinilestradiol) durante 6 meses reduziu os níveis de MMP-2, tanto nas controles saudáveis quanto nas portadoras de SOP, além de reduzir os níveis de TIMP-2 e TIMP-1 nas primeiras. Sendo assim, a diminuição do hiperandrogenismo com o uso do anticoncepcional oral nas pacientes com SOP pode possuir efeito benéfico, uma vez que diminui os níveis de MMP-2 plasmática, o que pode contribuir também para a redução do risco cardiovascular nessas mulheres. Entretanto, são necessários estudos maiores e com maior tempo de tratamento para confirmar os efeitos benéficos ou não do uso de anticoncepcional oral em pacientes com SOP.

REFERÊNCIAS BIBLIOGRÁFICAS

REFERÊNCIAS BIBLIOGRÁFICAS

1. Carmina E, Lobo RA (1999) Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. *J Clin Endocrinol Metab* 84 (6):1897-1899
2. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) (2004). *Hum Reprod* 19 (1):41-47
3. Diamanti-Kandarakis E, Papavassiliou AG (2006) Molecular mechanisms of insulin resistance in polycystic ovary syndrome. *Trends Mol Med* 12 (7):324-332
4. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 90 (4):1929-1935
5. Legro RS, Kusanman AR, Dodson WC, Dunaif A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. *J Clin Endocrinol Metab* 84 (1):165-169
6. Legro RS, Kusanman AR, Dunaif A (2001) Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. *Am J Med* 111 (8):607-613
7. Norman RJ (2001) Obesity, polycystic ovary syndrome and anovulation--how are they interrelated? *Curr Opin Obstet Gynecol* 13 (3):323-327
8. Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Paterakis T, Lekakis J, Panidis D (2006) Inflammatory and endothelial markers in women with polycystic ovary syndrome. *Eur J Clin Invest* 36 (10):691-697
9. Gonzalez F, Rote NS, Minium J, Kirwan JP (2009) Evidence of proatherogenic inflammation in polycystic ovary syndrome. *Metabolism* 58 (7):954-962
10. Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S, Mittermayer F, Wolzt M, Krzyzanowska K, Randeve H, Schernthaner G, Lehnert H (2008) Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. *J Clin Endocrinol Metab* 93 (1):82-90
11. Cussons AJ, Stuckey BG, Watts GF (2006) Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. *Atherosclerosis* 185 (2):227-239
12. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP (2007) Pathophysiology and types of dyslipidemia in PCOS. *Trends Endocrinol Metab* 18 (7):280-285
13. Orio F, Jr., Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G, Colao A (2004) Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 89 (9):4588-4593
14. Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A (2005) Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. *Hum Reprod* 20 (9):2409-2413
15. Lakhani K, Seifalian AM, Hardiman P (2002) Impaired carotid viscoelastic properties in women with polycystic ovaries. *Circulation* 106 (1):81-85
16. Soares GM, Vieira CS, Martins WP, Franceschini SA, dos Reis RM, Silva de Sa MF, Ferriani RA (2009) Increased arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS) without comorbidities: one more characteristic inherent to the syndrome? *Clin Endocrinol (Oxf)* 71 (3):406-411

REFERÊNCIAS BIBLIOGRÁFICAS

17. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ (2008) Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. *J Clin Endocrinol Metab* 93 (4):1276-1284
18. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS (2004) Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 89 (11):5454-5461
19. Galis ZS, Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. *Circulation research* 90 (3):251-262
20. Galis ZS, Sukhova GK, Lark MW, Libby P (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. *J Clin Invest* 94 (6):2493-2503
21. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. *Circulation* 105 (9):1135-1143
22. Reich R, Tsafriri A, Mechanic GL (1985) The involvement of collagenolysis in ovulation in the rat. *Endocrinology* 116 (2):522-527
23. Cooke RG, 3rd, Nothnick WB, Komar C, Burns P, Curry TE, Jr. (1999) Collagenase and gelatinase messenger ribonucleic acid expression and activity during follicular development in the rat ovary. *Biol Reprod* 61 (5):1309-1316
24. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. *Circulation research* 92 (8):827-839
25. Chang C, Werb Z (2001) The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. *Trends Cell Biol* 11 (11):S37-43
26. Raffetto JD, Khalil RA (2008) Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. *Biochem Pharmacol* 75 (2):346-359
27. Ra HJ, Parks WC (2007) Control of matrix metalloproteinase catalytic activity. *Matrix Biol* 26 (8):587-596
28. Clark IM, Swingle TE, Sampieri CL, Edwards DR (2008) The regulation of matrix metalloproteinases and their inhibitors. *The international journal of biochemistry & cell biology* 40 (6-7):1362-1378
29. Parks WC, Wilson CL, Lopez-Boado YS (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. *Nat Rev Immunol* 4 (8):617-629
30. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y (2005) Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. *J Clin Invest* 115 (3):599-609
31. Romanic AM, Harrison SM, Bao W, Burns-Kurtis CL, Pickering S, Gu J, Grau E, Mao J, Sathe GM, Ohlstein EH, Yue TL (2002) Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. *Cardiovasc Res* 54 (3):549-558

REFERÊNCIAS BIBLIOGRÁFICAS

32. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT (2002) Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. *J Clin Invest* 110 (5):625-632
33. Dhingra R, Pencina MJ, Schrader P, Wang TJ, Levy D, Pencina K, Siwik DA, Colucci WS, Benjamin EJ, Vasan RS (2009) Relations of matrix remodeling biomarkers to blood pressure progression and incidence of hypertension in the community. *Circulation* 119 (8):1101-1107
34. Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K, Ashby MJ, Cockcroft JR, Wilkinson IB (2005) Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. *Arterioscler Thromb Vasc Biol* 25 (2):372
35. Spinale FG (2002) Matrix metalloproteinases: regulation and dysregulation in the failing heart. *Circ Res* 90 (5):520-530
36. Guimaraes DA, Rizzi E, Ceron CS, Oliveira AM, Oliveira DM, Castro MM, Tirapelli CR, Gerlach RF, Tanus-Santos JE (2011) Doxycycline dose-dependently inhibits MMP-2-mediated vascular changes in 2K1C hypertension. *Basic Clin Pharmacol Toxicol* 108 (5):318-325
37. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL, Gerlach RF, Tanus-Santos JE (2008) Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. *Atherosclerosis* 198 (2):320-331
38. Castro MM, Rizzi E, Rodrigues GJ, Ceron CS, Bendhack LM, Gerlach RF, Tanus-Santos JE (2009) Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. *Free Radic Biol Med* 46 (9):1298-1307
39. Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P, Olivotti L, Rossettin P, Barsotti A, Ghigliotti G (2003) Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. *Eur J Clin Invest* 33 (8):648-656
40. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T (1998) Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. *J Am Coll Cardiol* 32 (2):368-372
41. Yamazaki T, Lee JD, Shimizu H, Uzui H, Ueda T (2004) Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. *Eur J Heart Fail* 6 (1):41-45
42. Newby AC (2005) Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. *Physiol Rev* 85 (1):1-31
43. Liapis CD, Paraskevas KI (2003) The pivotal role of matrix metalloproteinases in the development of human abdominal aortic aneurysms. *Vasc Med* 8 (4):267-271
44. Kuzuya M, Nakamura K, Sasaki T, Cheng XW, Itohara S, Iguchi A (2006) Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. *Arterioscler Thromb Vasc Biol* 26 (5):1120-1125
45. Li Z, Li L, Zielke HR, Cheng L, Xiao R, Crow MT, Stetler-Stevenson WG, Froehlich J, Lakatta EG (1996) Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. *Am J Pathol* 148 (1):121-128
46. Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG, et al. (1994) Migration of cultured vascular

REFERÊNCIAS BIBLIOGRÁFICAS

- smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. *Circ Res* 75 (1):41-54
47. Palombo D, Maione M, Cifiello BI, Udini M, Maggio D, Lupo M (1999) Matrix metalloproteinases. Their role in degenerative chronic diseases of abdominal aorta. *J Cardiovasc Surg (Torino)* 40 (2):257-260
48. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L (2003) Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. *Circulation* 107 (12):1579-1585
49. Tayebjee MH, Lip GY, Tan KT, Patel JV, Hughes EA, MacFadyen RJ (2005) Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. *Am J Cardiol* 96 (3):339-345
50. Molloy KJ, Thompson MM, Jones JL, Schwalbe EC, Bell PR, Naylor AR, Loftus IM (2004) Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. *Circulation* 110 (3):337-343
51. Sluijter JP, Pulskens WP, Schoneveld AH, Velema E, Strijder CF, Moll F, de Vries JP, Verheijen J, Hanemaaijer R, de Kleijn DP, Pasterkamp G (2006) Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. *Stroke* 37 (1):235-239
52. Turu MM, Krupinski J, Catena E, Rosell A, Montaner J, Rubio F, Alvarez-Sabin J, Cairols M, Badimon L (2006) Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. *Atherosclerosis* 187 (1):161-169
53. Tuomainen AM, Nyyssonen K, Laukkanen JA, Tervahartiala T, Tuomainen TP, Salonen JT, Sorsa T, Pussinen PJ (2007) Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. *Arterioscler Thromb Vasc Biol* 27 (12):2722-2728
54. Rizzi E, Castro MM, Prado CM, Silva CA, Fazan R, Jr., Rossi MA, Tanus-Santos JE, Gerlach RF (2010) Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. *J Card Fail* 16 (7):599-608
55. Rizzi E, Castro MM, Fernandes K, Barbosa F, Jr., Arisi GM, Garcia-Cairasco N, Bendhack LM, Tanus-Santos JE, Gerlach RF (2009) Evidence of early involvement of matrix metalloproteinase-2 in lead-induced hypertension. *Arch Toxicol* 83 (5):439-449
56. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, Thompson MM (2000) Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. *Stroke* 31 (1):40-47
57. Schulz R (2007) Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. *Annu Rev Pharmacol Toxicol* 47:211-242
58. Fontana V, Silva PS, Gerlach RF, Tanus-Santos JE (2012) Circulating matrix metalloproteinases and their inhibitors in hypertension. *Clin Chim Acta* 413 (7-8):656-662

REFERÊNCIAS BIBLIOGRÁFICAS

59. Kandalam V, Basu R, Abraham T, Wang X, Soloway PD, Jaworski DM, Oudit GY, Kassiri Z (2010) TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. *Circ Res* 106 (4):796-808
60. Lovelock JD, Baker AH, Gao F, Dong JF, Bergeron AL, McPheat W, Sivasubramanian N, Mann DL (2005) Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. *Am J Physiol Heart Circ Physiol* 288 (2):H461-468
61. Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, Gillijns H, Herijgers P, Flameng W, Carmeliet P, Van de Werf F, Pinto YM, Janssens S (2005) Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. *Circulation* 112 (8):1136-1144
62. Lambert E, Dasse E, Haye B, Petitfrere E (2004) TIMPs as multifacial proteins. *Crit Rev Oncol Hematol* 49 (3):187-198
63. Worley JR, Thompkins PB, Lee MH, Hutton M, Soloway P, Edwards DR, Murphy G, Knauper V (2003) Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). *Biochem J* 372 (Pt 3):799-809
64. Cowell S, Knauper V, Stewart ML, D'Ortho MP, Stanton H, Hembry RM, Lopez-Otin C, Reynolds JJ, Murphy G (1998) Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. *Biochem J* 331 (Pt 2) (Pt 2):453-458
65. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R (2002) Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. *Circulation* 106 (12):1543-1549
66. Fernandez-Patron C, Radomski MW, Davidge ST (1999) Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. *Circ Res* 85 (10):906-911
67. Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST (2000) Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. *Circ Res* 87 (8):670-676
68. Martinez A, Oh HR, Unsworth EJ, Bregonzio C, Saavedra JM, Stetler-Stevenson WG, Cuttitta F (2004) Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. *Biochem J* 383 (Pt. 3):413-418
69. Kato R, Momiyama Y, Ohmori R, Taniguchi H, Nakamura H, Ohsuzu F (2005) Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. *Circ J* 69 (9):1035-1040
70. Liu B, Cai LY, Lv HM, Xia L, Zhang YJ, Zhang HX, Guan YM (2008) Raised serum levels of matrix metalloproteinase-9 in women with polycystic ovary syndrome and its association with insulin-like growth factor binding protein-1. *Gynecol Endocrinol* 24 (5):285-288
71. Diamanti-Kandarakis E, Livadas S, Kandarakis SA, Margeli A, Papassotiriou I (2008) Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly

REFERÊNCIAS BIBLIOGRÁFICAS

- lower in women with polycystic ovary syndrome: hint of a protective mechanism? *Eur J Endocrinol* 158 (4):525-531
72. Lewandowski KC, Komorowski J, O'Callaghan CJ, Tan BK, Chen J, Prelevic GM, Randeva HS (2006) Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. *J Clin Endocrinol Metab* 91 (3):1173-1177
 73. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE (2007) Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. *Clin Biochem* 40 (1-2):119-123
 74. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE (2005) Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. *Anal Biochem* 344 (1):147-149
 75. Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos JE (2005) Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. *Clin Biochem* 38 (5):410-414
 76. Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, Pavlaki A, Stergianos S, Poulasouchidou M, Tzellos TG, Makedos A, Chourdakis M, Tarlatzis BC (2011) Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. *Hum Reprod Update* 17 (6):741-760
 77. Derosa G, Ferrari I, D'Angelo A, Tinelli C, Salvadeo SA, Ciccarelli L, Piccinni MN, Gravina A, Ramondetti F, Maffioli P, Cicero AF (2008) Matrix metalloproteinase-2 and -9 levels in obese patients. *Endothelium* 15 (4):219-224
 78. Andrade VL, Petruceli E, Belo VA, Andrade-Fernandes CM, Caetano Russi CV, Bosco AA, Tanus-Santos JE, Sandrim VC (2012) Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women. *Clin Biochem* 45 (6):412-415
 79. Kosmala W, Plaksej R, Przewlocka-Kosmala M, Kuliczowska-Plaksej J, Bednarek-Tupikowska G, Mazurek W (2008) Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function. *Int J Obes (Lond)* 32 (5):763-771
 80. Boden G, Song W, Kresge K, Mozzoli M, Cheung P (2008) Effects of hyperinsulinemia on hepatic metalloproteinases and their tissue inhibitors. *Am J Physiol Endocrinol Metab* 295 (3):E692-697
 81. Boden G, Song W, Pashko L, Kresge K (2008) In vivo effects of insulin and free fatty acids on matrix metalloproteinases in rat aorta. *Diabetes* 57 (2):476-483
 82. Norman RJ, Dewailly D, Legro RS, Hickey TE (2007) Polycystic ovary syndrome. *Lancet* 370 (9588):685-697
 83. Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P (2006) Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. *J Clin Endocrinol Metab* 91 (10):3922-3927
 84. Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF (2007) Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. *Hum Reprod* 22 (12):3197-3203
 85. Barrett-Connor E, Goodman-Gruen D (1995) Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. *Bmj* 311 (7014):1193-1196

REFERÊNCIAS BIBLIOGRÁFICAS

86. Ouyang P, Vaidya D, Dobs A, Golden SH, Szklo M, Heckbert SR, Kopp P, Gapstur SM (2009) Sex hormone levels and subclinical atherosclerosis in postmenopausal women: the Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis* 204 (1):255-261
87. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD (2001) Polycystic ovary syndrome is associated with endothelial dysfunction. *Circulation* 103 (10):1410-1415
88. Mantzoros CS, Georgiadis EI, Young R, Evagelopoulou C, Khoury S, Katsilambros N, Sowers JR (1995) Relative androgenicity, blood pressure levels, and cardiovascular risk factors in young healthy women. *Am J Hypertens* 8 (6):606-614
89. Chen MJ, Yang WS, Yang JH, Chen CL, Ho HN, Yang YS (2007) Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. *Hypertension* 49 (6):1442-1447
90. Adams MR, Williams JK, Kaplan JR (1995) Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. *Arterioscler Thromb Vasc Biol* 15 (5):562-570
91. Vrbikova J, Cibula D (2005) Combined oral contraceptives in the treatment of polycystic ovary syndrome. *Hum Reprod Update* 11 (3):277-291
92. Liao X, Thrasher JB, Pelling J, Holzbeierlein J, Sang QX, Li B (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. *Endocrinology* 144 (5):1656-1663
93. Li BY, Liao XB, Fujito A, Thrasher JB, Shen FY, Xu PY (2007) Dual androgen-response elements mediate androgen regulation of MMP-2 expression in prostate cancer cells. *Asian J Androl* 9 (1):41-50
94. Natoli AK, Medley TL, Ahimastos AA, Drew BG, Thearle DJ, Dilley RJ, Kingwell BA (2005) Sex steroids modulate human aortic smooth muscle cell matrix protein deposition and matrix metalloproteinase expression. *Hypertension* 46 (5):1129-1134
95. Henmi H, Endo T, Nagasawa K, Hayashi T, Chida M, Akutagawa N, Iwasaki M, Kitajima Y, Kiya T, Nishikawa A, Manase K, Kudo R (2001) Lysyl oxidase and MMP-2 expression in dehydroepiandrosterone-induced polycystic ovary in rats. *Biol Reprod* 64 (1):157-162
96. Vieira CS, Martins WP, Fernandes JB, Soares GM, Dos Reis RM, de Sa MF, Ferriani RA (2012) The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. *Contraception* 28:28
97. Guido M, Romualdi D, Campagna G, Ricciardi L, Bompiani A, Lanzzone A (2010) Ethinylestradiol-chlormadinone acetate combination for the treatment of hirsutism and hormonal alterations of normal-weight women with polycystic ovary syndrome: evaluation of the metabolic impact. *Reprod Sci* 17 (8):767-775

ANEXOS

**SPRINGER LICENSE
TERMS AND CONDITIONS**

Jun 15, 2012

This is a License Agreement between Valéria Gomes ("You") and Springer ("Springer") provided by Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and conditions provided by Springer, and the payment terms and conditions.

All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form.

License Number	2930020245715
License date	Jun 15, 2012
Licensed content publisher	Springer
Licensed content publication	Molecular and Cellular Biochemistry
Licensed content title	Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome
Licensed content author	Valéria A. Gomes
Licensed content date	Jan 1, 2011
Volume number	353
Issue number	1
Type of Use	Thesis/Dissertation
Portion	Full text
Number of copies	10
Author of this Springer article	Yes and you are the sole author of the new work
Order reference number	
Title of your thesis / dissertation	"Efeitos do anticoncepcional oral sobre as alterações de metaloproteínas da matriz extracelular em pacientes com síndrome do ovário policístico"
Expected completion date	Jul 2012
Estimated size(pages)	67
Total	0.00 USD
Terms and Conditions	

Introduction

The publisher for this copyrighted material is Springer Science + Business Media. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at <http://myaccount.copyright.com>).

Limited License

With reference to your request to reprint in your thesis material on which Springer Science and Business Media control the copyright, permission is granted, free of charge, for the use indicated in your enquiry.

Licenses are for one-time use only with a maximum distribution equal to the number that you identified in the licensing process.

This License includes use in an electronic form, provided its password protected or on the university's intranet or repository, including UMI (according to the definition at the Sherpa website: <http://www.sherpa.ac.uk/romeo/>). For any other electronic use, please contact Springer at (permissions.dordrecht@springer.com or permissions.heidelberg@springer.com).

The material can only be used for the purpose of defending your thesis, and with a maximum of 100 extra copies in paper.

Although Springer holds copyright to the material and is entitled to negotiate on rights, this license is only valid, provided permission is also obtained from the (co) author (address is given with the article/chapter) and provided it concerns original material which does not carry references to other sources (if material in question appears with credit to another source, authorization from that source is required as well).

Permission free of charge on this occasion does not prejudice any rights we might have to charge for reproduction of our copyrighted material in the future.

Altering/Modifying Material: Not Permitted

You may not alter or modify the material in any manner. Abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of the author(s) and/or Springer Science + Business Media. (Please contact Springer at (permissions.dordrecht@springer.com or permissions.heidelberg@springer.com))

Reservation of Rights

Springer Science + Business Media reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.

Copyright Notice:Disclaimer

You must include the following copyright and permission notice in connection with any reproduction of the licensed material: "Springer and the original publisher /journal title, volume, year of publication, page, chapter/article title, name(s) of author(s), figure number(s), original copyright notice) is given to the publication in which the material was originally published, by adding; with kind permission from Springer Science and Business Media"

Warranties: None

Example 1: Springer Science + Business Media makes no representations or warranties with respect to the licensed material.

Example 2: Springer Science + Business Media makes no representations or warranties with

respect to the licensed material and adopts on its own behalf the limitations and disclaimers established by CCC on its behalf in its Billing and Payment terms and conditions for this licensing transaction.

Indemnity

You hereby indemnify and agree to hold harmless Springer Science + Business Media and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license.

No Transfer of License

This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without Springer Science + Business Media's written permission.

No Amendment Except in Writing

This license may not be amended except in a writing signed by both parties (or, in the case of Springer Science + Business Media, by CCC on Springer Science + Business Media's behalf).

Objection to Contrary Terms

Springer Science + Business Media hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and Springer Science + Business Media (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall control.

Jurisdiction

All disputes that may arise in connection with this present License, or the breach thereof, shall be settled exclusively by arbitration, to be held in The Netherlands, in accordance with Dutch law, and to be conducted under the Rules of the 'Netherlands Arbitrage Instituut' (Netherlands Institute of Arbitration). **OR:**

All disputes that may arise in connection with this present License, or the breach thereof, shall be settled exclusively by arbitration, to be held in the Federal Republic of Germany, in accordance with German law.

Other terms and conditions:

v1.3

If you would like to pay for this license now, please remit this license along with your payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be invoiced within 48 hours of the license date. Payment should be in the form of a check or money order referencing your account number and this invoice number RLNK500799830.

Once you receive your invoice for this order, you may pay your invoice by credit card. Please follow instructions provided at that time.

**Make Payment To:
Copyright Clearance Center**

Dept 001
P.O. Box 843006
Boston, MA 02284-3006

For suggestions or comments regarding this order, contact RightsLink Customer Support: customer care@copyright.com or +1-877-622-5543 (toll free in the US) or +1-978-646-2777.

Gratis licenses (referencing \$0 in the Total field) are free. Please retain this printable license for your reference. No payment is required.

**JOHN WILEY AND SONS LICENSE
TERMS AND CONDITIONS**

Jun 15, 2012

This is a License Agreement between Valéria Gomes ("You") and John Wiley and Sons ("John Wiley and Sons") provided by Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and conditions provided by John Wiley and Sons, and the payment terms and conditions.

All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form.

License Number	2930020997437
License date	Jun 15, 2012
Licensed content publisher	John Wiley and Sons
Licensed content publication	Basic & Clinical Pharmacology & Toxicology
Licensed content title	Oral Contraceptive Containing Chlormadinone Acetate and Ethinylestradiol Reduces Plasma Concentrations of Matrix Metalloproteinase-2 in Women with Polycystic Ovary Syndrome
Licensed content author	Valéria A. Gomes, Carolina S. Vieira, Anna L. Jacob-Ferreira, Vanessa A. Belo, Gustavo M. Soares, Janaina B. França, Rui A. Ferriani, Jose E. Tanus-Santos
Licensed content date	May 11, 2012
Start page	n/a
End page	n/a
Type of use	Dissertation/Thesis
Requestor type	Author of this Wiley article
Format	Print and electronic
Portion	Full article
Will you be translating?	No
Order reference number	
Total	0.00 USD
Terms and Conditions	

TERMS AND CONDITIONS

This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. or one of its group companies (each a "Wiley Company") or a society for whom a Wiley Company has exclusive publishing rights in relation to a particular journal (collectively WILEY). By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the billing and payment terms and conditions established by the Copyright Clearance Center Inc., ("CCC's Billing and Payment terms and conditions"), at the time that you opened your Rightslink account (these are available at any time at <http://myaccount.copyright.com>)

Terms and Conditions

1. The materials you have requested permission to reproduce (the "Materials") are protected by copyright.

2. You are hereby granted a personal, non-exclusive, non-sublicensable, non-transferable, worldwide, limited license to reproduce the Materials for the purpose specified in the licensing process. This license is for a one-time use only with a maximum distribution equal to the number that you identified in the licensing process. Any form of republication granted by this licence must be completed within two years of the date of the grant of this licence (although copies prepared before may be distributed thereafter). The Materials shall not be used in any other manner or for any other purpose. Permission is granted subject to an appropriate acknowledgement given to the author, title of the material/book/journal and the publisher. You shall also duplicate the copyright notice that appears in the Wiley publication in your use of the Material. Permission is also granted on the understanding that nowhere in the text is a previously published source acknowledged for all or part of this Material. Any third party material is expressly excluded from this permission.

3. With respect to the Materials, all rights are reserved. Except as expressly granted by the terms of the license, no part of the Materials may be copied, modified, adapted (except for minor reformatting required by the new Publication), translated, reproduced, transferred or distributed, in any form or by any means, and no derivative works may be made based on the Materials without the prior permission of the respective copyright owner. You may not alter, remove or suppress in any manner any copyright, trademark or other notices displayed by the Materials. You may not license, rent, sell, loan, lease, pledge, offer as security, transfer or assign the Materials, or any of the rights granted to you hereunder to any other person.

4. The Materials and all of the intellectual property rights therein shall at all times remain the exclusive property of John Wiley & Sons Inc or one of its related companies (WILEY) or their respective licensors, and your interest therein is only that of having possession of and the right to reproduce the Materials pursuant to Section 2 herein during the continuance of this Agreement. You agree that you own no right, title or interest in or to the Materials or any of the intellectual property rights therein. You shall have no rights hereunder other than the license as provided for above in Section 2. No right, license or interest to any trademark, trade name, service mark or other branding ("Marks") of WILEY or its licensors is granted hereunder, and you agree that you shall not assert any such right, license or interest with respect thereto.

5. NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY, EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY, INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED BY YOU.

6. WILEY shall have the right to terminate this Agreement immediately upon breach of this Agreement by you.

7. You shall indemnify, defend and hold harmless WILEY, its Licensors and their respective directors, officers, agents and employees, from and against any actual or threatened claims, demands, causes of action or proceedings arising from any breach of this Agreement by you.

8. IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT, NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN.

9. Should any provision of this Agreement be held by a court of competent jurisdiction to be illegal, invalid, or unenforceable, that provision shall be deemed amended to achieve as nearly as possible the same economic effect as the original provision, and the legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby.

10. The failure of either party to enforce any term or condition of this Agreement shall not constitute a waiver of either party's right to enforce each and every term and condition of this Agreement. No breach under this agreement shall be deemed waived or excused by either party unless such waiver or consent is in writing signed by the party granting such waiver or consent. The waiver by or consent of a party to a breach of any provision of this Agreement shall not operate or be construed as a waiver of or consent to any other or subsequent breach by such other party.

11. This Agreement may not be assigned (including by operation of law or otherwise) by you without WILEY's prior written consent.

12. Any fee required for this permission shall be non-refundable after thirty (30) days from receipt.

13. These terms and conditions together with CCC's Billing and Payment terms and conditions (which are incorporated herein) form the entire agreement between you and WILEY concerning this licensing transaction and (in the absence of fraud) supersedes all prior agreements and representations of the parties, oral or written. This Agreement may not be amended except in writing signed by both parties. This Agreement shall be binding upon and inure to the benefit of the parties' successors, legal representatives, and authorized assigns.

14. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall prevail.

15. WILEY expressly reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.

16. This Agreement will be void if the Type of Use, Format, Circulation, or Requestor Type was misrepresented during the licensing process.

17. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, USA, without regards to such state's conflict of law rules. Any legal action, suit or proceeding arising out of or relating to these Terms and Conditions or the breach thereof shall be instituted in a court of competent jurisdiction in New York County in the State of New York in the United States of America and each party hereby consents and submits to the personal jurisdiction of such court, waives any objection to venue in such court and consents to service of process by registered or certified mail, return receipt requested, at the last known address of such party.

Wiley Open Access Terms and Conditions

All research articles published in Wiley Open Access journals are fully open access: immediately freely available to read, download and share. Articles are published under the terms of the [Creative Commons Attribution Non Commercial License](#), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The license is subject to the Wiley Open Access terms and conditions: Wiley Open Access articles are protected by copyright and are posted to repositories and websites in accordance with the terms of the [Creative Commons Attribution Non Commercial License](#). At the time of deposit, Wiley Open Access articles include all changes made during peer review, copyediting, and publishing. Repositories and websites that host the article are responsible for incorporating any publisher-supplied amendments or retractions issued subsequently. Wiley Open Access articles are also available without charge on Wiley's publishing platform, **Wiley Online Library** or any successor sites.

Use by non-commercial users

For non-commercial and non-promotional purposes individual users may access, download, copy, display and redistribute to colleagues Wiley Open Access articles, as well as adapt, translate, text- and data-mine the content subject to the following conditions:

- The authors' moral rights are not compromised. These rights include the right of "paternity" (also known as "attribution" - the right for the author to be identified as such) and "integrity" (the right for the author not to have the work altered in such a way that the author's reputation or integrity may be impugned).
- Where content in the article is identified as belonging to a third party, it is the obligation of the user to ensure that any reuse complies with the copyright policies of the owner of that content.
- If article content is copied, downloaded or otherwise reused for non-commercial research and education purposes, a link to the appropriate bibliographic citation (authors, journal, article title, volume, issue, page numbers, DOI and the link to the definitive published version on Wiley Online Library) should be maintained. Copyright notices and disclaimers must not be deleted.
- Any translations, for which a prior translation agreement with Wiley has not been agreed, must prominently display the statement: "This is an unofficial translation of an article that appeared in a Wiley publication. The publisher has not endorsed this translation."

Use by commercial "for-profit" organisations

Use of Wiley Open Access articles for commercial, promotional, or marketing purposes requires further explicit permission from Wiley and will be subject to a fee. Commercial purposes include:

- Copying or downloading of articles, or linking to such articles for further redistribution, sale or licensing;
- Copying, downloading or posting by a site or service that incorporates advertising with such content;
- The inclusion or incorporation of article content in other works or services (other than normal quotations with an appropriate citation) that is then available for sale or licensing, for a fee (for example, a compilation produced for marketing purposes, inclusion in a sales pack)
- Use of article content (other than normal quotations with appropriate citation) by for-profit organisations for promotional purposes
- Linking to article content in e-mails redistributed for promotional, marketing or educational purposes;
- Use for the purposes of monetary reward by means of sale, resale, licence, loan, transfer or other form of commercial exploitation such as marketing products
- Print reprints of Wiley Open Access articles can be purchased from:
corporatesales@wiley.com

Other Terms and Conditions:

BY CLICKING ON THE "I AGREE..." BOX, YOU ACKNOWLEDGE THAT YOU HAVE READ AND FULLY UNDERSTAND EACH OF THE SECTIONS OF AND PROVISIONS SET FORTH IN THIS AGREEMENT AND THAT YOU ARE IN

AGREEMENT WITH AND ARE WILLING TO ACCEPT ALL OF YOUR OBLIGATIONS AS SET FORTH IN THIS AGREEMENT.

v1.7

If you would like to pay for this license now, please remit this license along with your payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be invoiced within 48 hours of the license date. Payment should be in the form of a check or money order referencing your account number and this invoice number RLNK500799832.

Once you receive your invoice for this order, you may pay your invoice by credit card. Please follow instructions provided at that time.

**Make Payment To:
Copyright Clearance Center
Dept 001
P.O. Box 843006
Boston, MA 02284-3006**

For suggestions or comments regarding this order, contact RightsLink Customer Support: customercare@copyright.com or +1-877-622-5543 (toll free in the US) or +1-978-646-2777.

Gratis licenses (referencing \$0 in the Total field) are free. Please retain this printable license for your reference. No payment is required.